BioSpectrum India May 2022

"We Communicate
directly with
Life-Science
Leaders and
BioPharma
Executives
World-Wide"

www.biospectrumasia.com www.biospectrumindia.com

For More information , Please contact [email protected]

Xell is now part of Sartorius

Xell’s Contract Manufacturing Service Running out of buffer
or cell culture medium?
The Solution to your
Supply Chain Challenges Visit our website
and take advantage
Production plant based in Germany
100% animal-origin free facility of Xell’s shortest
Individual, flexible and fast solutions lead times:

For dry powder formulations and liquid
formulations (culture media, feed supplements,
buffers and more)

Customized packaging solutions available
(e.g. HDPE drums, bags etc.)

Sartorius Xell GmbH (Headquarters) RRR Labs Pvt Ltd (Distributor)

Schloss Holte, Germany www.xell.de Mumbai, India www.rrrlabs.com

+49 5207 9597 200 [email protected] +91 22 2783 3655 [email protected]

4 BIO CONTENT BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

26 20 COVER
DESIGN BY:
BIOCON LTD COVERSTORY DOMINIX STRATEGIC
DESIGN PVT. LTD.
Indian biopharma industry

HITS Rs 33K Cr WITH

13% GROWTH
IN 2020-21

Amidst the pandemic, the Indian
Biopharma Industry, with over 300
companies, has witnessed a good

growth of 13 per cent, 2 per cent
less than the previous year’s 15 per
cent growth rate. This growth was
largely driven by performance of
the Indian biopharma companies
which have done very well as against
multinational companies. As a result,
the Indian Biopharma Industry has
crossed the Rs 33,000 crore mark for
the year 2020-21 over the previous

year’s figure of Rs 29,176 crore.
The Indian Biopharma industry,
comprising hormones, insulin, blood
products and vaccines recorded a
sales revenue of Rs 33,067 crore for

the year 2020-21.

21 25

Serum Institute SERUM INSTITUTE
of India Ltd OF INDIA LTD
continues to
DR. CYRUS S. ADAR POONAWALLA
lead the Indian POONAWALLA Chief Executive Officer
Biopharmaceutical Chairman and Managing
Director
Industry
at No 1 position

27 28 29

SANOFI NOVO NORDISK BHARAT BIOTECH
HEALTHCARE INDIA PVT LTD INTERNATIONAL
INDIA PVT LTD LTD

DR KIRAN DR KI VIKRANT SHROTRIYA DR KRISHNA ELLA
MAZUMDAR-SHAW VARAPRASAD REDDY Managing Director Chairman and
Executive Chairperson Director Managing Director

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIO CONTENT 5

30 Top Video Dr Balasubramanian
V, Co-founder, and
31 BIOLOGICAL E Chief Operating
LTD Officer, Bugworks
RELIANCE LIFE talks in detail about
SCIENCES PVT LTD MAHIMA DATLA his startup and the
Managing Director work being done in
the field of anti-
32 microbial resistance
(AMR).
SANOFI
INDIA LTD

KV SUBRAMANIAM RODOLFO HROSZ Scan the QR Code »
President Managing Director
Rafiq Somani,
33 34 Area Vice President
- India and South
INTAS GLAXOSMITHKLINE Asia Pacific at
PHARMACEUTICALS PHARMACEUTICALS ANSYS, Inc is
LTD LTD of the view that
computational fluid
dynamics (CFD) is
paving the way for
successful patient-
specific medical
treatments.

BINISH CHUDGAR SRIDHAR VENKATESH Scan the QR Code »
Managing Director Managing Director
Deepak Sharma,
Regulars Co-founder and
Chief Executive
BioEdit .......................................................................... 06 Officer, MedLern
BioMail ......................................................................... 08 tells us whether
Start Up News............................................................. 10 Indian healthcare
Policy and Regulatory News..................................... 12 professionals
Finance News.............................................................. 14 are ready for
Company News.......................................................... 16 instructorless
R&D News.................................................................... 48 online training or
Supplier News............................................................. 49 not.
Let’s Talk Health.......................................................... 50
Scan the QR Code »

6 BIO EDIT BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

SIntnroonvga-taivrme PTiapcsticGseneric

The pleasantries exchanged by Dr Tedros about deaths and bodies floating in river and people
Ghebreyesus, Director General (DG), World running door to door for Oxygen cylinders in the second
Health Organisation (WHO) and Prime Minister wave, stalling the release of the report would be a blotch
Narendra Modi at events held in Gujarat during the on the government’s intention of stalling the release of
former’s recent 3-day visit to India were no way an report, even though its point of flawed methodology may
indicator of what is brewing between the WHO and have some merit.
India. Their differences stem from a WHO report on the
number of deaths caused by COVID-19. Another bone As if this stand-off was not enough, the WHO has
of contention is that the WHO has suspended Covaxin suspended supply of Covaxin vaccine (manufactured
supply through United Nations (UN) agencies. by Bharat Biotech) to the United Nations (UN)
procurement agencies, citing deficiencies in good
The international media has alleged that the manufacturing practices (GMP). It conducted a
release of WHO’s estimate of global toll caused by the site inspection in March and identified some GMP
COVID-19 pandemic is delayed due to objections raised deficiencies which need to be removed by the process
over it by India. More than a year ago, WHO experts and facility upgradation. The company is developing a
went on a fact-finding mission to ascertain the actual corrective plan for submission to authorities – the WHO
number of deaths, which it estimates at 15 million (till and Drugs Controller General of India (DCGI). But, as
end of 2021) – more than double of six million, a total an interim precautionary measure it has suspended
of deaths reported by countries individually. In the case vaccine production for export which is likely to interrupt
of India, the WHO’s estimate is almost eight times more the supply.
than the country’s official figure of 5.2 lakh.
However, WHO’s brief statement on the topic is a
India has objected to the ‘flawed’ methodology little confusing since in the same statement it says as
used by the WHO to arrive at the death toll in India, per the available data vaccine is effective and no safety
claiming that the process was neither collaborative concerns exist. In view of the suspension it recommends
nor representative. In short, the process did not hold that the countries using the vaccine take action as
the level of ‘scientific rigor’ and rational scrutiny that appropriate.
is expected from the WHO. Basically, India is against
applying the similar standards to all countries to count Experts are baffled over the contradictions in the
the deaths as conditions differ country wise. Some other statement. When the vaccine is safe and effective
countries like China and Iran have also put down the then what is the need for suspension. If suspension is
report. due to interruption in supply caused by optimisation
of the facility, then why are the countries advised to
However, the logical points raised by the take appropriate action. Also, there is no mention of
government in support of its contention is not yet clear. the possible appropriate action. The statement is also
Although, in principle, there may be some substance in silent about the type and/or extent of the deficiencies
the government’s argument, allowing WHO to publish in GMPs. But it is also important to note that Brazil’s
the report and then pointing out the errors and flaws in drug regulating agency too had found deficiencies at the
methodology would have been a better approach. Then Bharat Biotech’s manufacturing facility about a year ago.
India’s position would have gained more weightage.
This is particularly important when our record keeping However, both the times, India’s drug regulator
hasn’t been up to the mark. What’s even perplexing is Central Drugs Standard Control Organisation (CDSCO)
that the government could not furnish any figures, even is silent over the issue. CDSCO should swing into action
to the Parliament, of the number of people who lost lives to remove any doubts, if any, from the people’s mind.
due to non-availability of O2 cylinders or the number It is important to instill confidence in Indian medicine
of daily wage workers walking home due to the initial products, internationally and even locally.
media-fueled fear psychosis about COVID-19 and the
subsequent loss of jobs. When media was full of reports Dr Milind Kokje
Chief Editor

[email protected]

HEKin1™ Media for COVID-19 Vaccine
CELLin1™ Production

Serum Free HEKin1TM for Recombinant COVID-19 Vaccine Production
& Animal
Component HEK-based vaccine manufacturing processes require a highly efficient and
Free Media productive medium at each step starting from cell banking, till cell expansion
Designed and virus production in bioreactor.
for Growth Try out our HEKin1TM, a fully optimized medium for production of HEK-based
of HEK293 & recombinant COVID-19 vaccine.
VERO Cells
CELLin1TM for Inactivated COVID-19 Vaccine Production
Scalability for use
in shake flasks & Vero is a potential host cell line used for SARS-CoV-2 virus replication &
bioreactors manufacturing of inactivated COVID-19 viral vaccine.
Try out our CELLin1TM, to achieve high viral titers using Vero cells in 2D and
3D cultures. CELLin1TM has also been optimized for production of other viral
vaccines using PK-15, MDCK and MDBK cells.

Save time with simplified Supports high cell
purification and density, culture longevity
downstream processing and increased yield

HiMediaLaboratories™ HIMEDIA BIOSCIENCES SERVIN G HUMANKIND

himedialabs.com

Tel : +91-22-6147 1919
Email : [email protected]

8 BIO MAIL BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

Vol 20; Issue 4; April 2022

Acknowledgements I wish to get a peep into certain developments on cataract
Great job on the cover story related to undruggable management of which there has been some recent
cancer. breakthroughs. Apparently aquaporins can now be
- Prof. Mohammad Husain, New Delhi administered through nano carriers and peptides. There
is some development of nano drops by Israel. In India,
34 nanorods of Aspirin are being tried by INSAT, Mohali. I
Thank you for the coverage on Mylab Discovery will be favoured to receive a reply from BioSpectrum, if
Solutions in the diagnostic/ medtech ranking survey in possible in the event there is some marked breakthrough.
the April edition. - Neeraj Gupt, Muzaffarnagar
- Hasmukh Rawal, Pune

Rapid advances in genetics, machine learning, I read your report on the Indian industrial enzymes
robotics, materials and bio-engineering coupled market covered in BioSpectrum February 2022 edition.
with all-time high interest in investments from I was quite impressed. I would like to know whether
both government and private sector in healthcare you can provide me with the latest market size data for
signal a bright future for diagnostics in India. industrial enzymes. Also is there any data available on
Thanks for the coverage and update on Shanmukha product wise market size, say Pectinase and Cellulase
Innovations in the diagnostic/medtech ranking market in India.
survey.
- Abhay Ekbote, Hyderabad
- Arun Balasubramanian, Bengaluru Clarification
We saw a message on the Association of diagnostics The revenue figure for Beacon Diagnostics Pvt Ltd
manufacturers India group of which we are a part during FY 20-21 was Rs 44.4 crore, as covered in
of, about the recent ranking survey on diagnostic/ BioSpectrum April 2022 edition. However, the
medtech sector. Promea Therapeutics would like to be company wishes to clarify that Beacon Group’s
considered next time and be a part of the recognised turnover stood at Rs 110.35 crore for FY 20-21. This
diagnostic companies with BioSpectrum so that we can includes Rs 44.4 crore for Beacon Diagnostics Pvt Ltd;
be ranked on the same. Rs 51.6 crore for Vector Biotek Pvt Ltd; and Rs 14. 3
crore for Biogeny Diagnostics Pvt Ltd.
- Surya Bijoy Varma, Hyderabad
- Editor

Vol 20; Issue 5; May 2022 MM Activ Sci-Tech Communications

Publisher & Managing Editor: South Region New Delhi INTERNATIONAL
Ravindra Boratkar Alok Srivastava Dr Manbeena Chawla Singapore
Editorial: National Business Head- Executive Editor MM Activ Singapore Pte. Ltd.
Chief Editor: Dr Milind Kokje Ad Sales & Marketing 103-104, Rohit House 3, Saradha Mani
[email protected] “NITON”, Block B, First Floor, Tolstoy Marg, Connaught Place, General Manager
Advisor - Content: Vijay Thombre 11/3, Palace Road, Bangalore 560001 New Delhi - 110 001 #08-08, High Street Centre,
Editor: Mobile: +91-9845128747 Mobile: +91-8861043732 1 North Bridge Road,
Narayan Kulkarni Tel.: +91-80-41131912/13 [email protected] Singapore - 179094
[email protected] [email protected] Tel: +65-63369142
Executive Editor: Fax:+65-63369145
Dr Manbeena Chawla Mumbai Pune [email protected]
[email protected] Ankit Kankar Ankur Hange
Sub Editor: Senior Manager - Business Development USA
Nitesh Pillai Digital Strategy & Growth Executive BioSpectrum Bureau
[email protected] 1st Floor, CIDCO Convention Ashirwad, 36/A/2, S.No. 270, MM Activ
Content Team: Center, Sector 30A, Vashi, Navi Pallod Farms, Baner Road, Pune- Sci-Tech Communications
Singapore: Hithaishi C. Bhaskar Mumbai, Maharashtra-400703. 411045 Mobile: +91-9579069369
[email protected] Mobile: +91-9579069369 Mobile: +91-9834745564 E-mail: [email protected]
Social Media Communications: [email protected] [email protected]
Poonam Bhosale Europe
[email protected] Nagpur BioSpectrum Bureau
CFO & Special Correspondent: Manisha Boratkar MM Activ
Manasee Kurlekar 402, Govind Apartments, Shankar Nagar Square, Sci-Tech Communications
[email protected] Nagpur - 440 010. Tel. +91-712-2555 249 Mobile: +91-9579069369
E-mail: [email protected]
Production & Design:
MM Activ Sci-Tech Communications ‘BioSpectrum’ monthly publication is owned by MM Activ Sci-Tech Communications Pvt. Ltd., Published
Anil Walunj and Printed by Ravindra Boratkar, Printed at Spectrum Offset, D2/4, Satyam Industrial Estate, Behind CDSS,
Erandawana, Pune - 411 038. and Published at ‘Ashirwad’, 36/A/s, S. No. 270, Pallod Farms, Baner Road, Near
Product & Marketing Bank of Baroda, Pune - 411 045. Editor: Narayan Kulkarni. Website: www.biospectrumindia.com
Ankit Kankar
[email protected]

Circulation, Subscription and
Media Enquiry:
Asmita Thakar
[email protected]

INDIGENOUS

INNOVATION

RANGE OF HEMATOLOGY ANALYZERS

• Sturdy Hardware • Enhanced Durability • Automatic Clot Clearing

Toll 1800 425 7151 / 1800 891 7251 / 1800 270 7151
Free

“Agappe Hills”, Pattimattom (PO), Dist. Ernakulam, Kerala - 683 562, India.
TEL: + 91 484 2867000 | [email protected] | www.agappe.com

10 START UP NEWS BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

Orange Koi Qure.ai secures $40M from
gets financial Novo Holdings, HealthQuad
support from
TDB Mumbai-based startup Qure.ai has secured $40 million in a funding
round led by Novo Holdings and HealthQuad, supported by existing
Paving the road ahead investor MassMutual Ventures. Qure.ai will use the new investment to
for medtech startups, extend and strengthen its global reach, especially in the US and Europe,
Technology Development and intensify product development for critical care and community
Board (TDB) has approved diagnostics. The startup has created a niche for itself with
financial support to advanced technology that reads and interprets medical images
Visakhapatnam-based like X-rays, CTs, and Ultrasounds in less than a minute,
startup Orange Koi for making equitable and high-quality
their project on ‘Metal healthcare a reality across the globe.
Injection Molding of Qure’s AI solutions are FDA-
Implants, Robotic approved, CE-certified, and
Surgical Instruments & evaluated by the World Health
Devices.’ The company Organisation.
aims at implementing the
Metal Injection Molding IIT-D startup Fabiosys develops
(MIM) process for the technology for antiviral fabric
manufacturing of medical
surgical instruments After three years of rigorous research & development, Fabiosys Innovations, a
and device components. deep-tech healthcare startup incubated at the Indian Institute of Technology,
MIM is a technology for Delhi (IIT-D), has developed an extremely affordable high-performance
manufacturing complex, medical textile Fabium, which destroys approximately 99.9 per cent of
precision, net shape the bacteria and viruses within 30 minutes. Ordinary antimicrobial fabric
components from either products available in the market inhibit microbes in a span of 24 hours & that
metal or ceramic powder. too with an unsatisfactory efficiency. This time span of 24 hours makes those
The potential of MIM lies antimicrobial fabric products impractical to be used in everyday life because a
in its ability to combine the typical bacterium doubles itself in a span of around 20-30 minutes. Fabium is
design flexibility of plastic developed using a technology called Hi-PAT, which makes it highly effective
injection moulding and against bacteria, viruses, & fungi. Fabium starts working within seconds of
the versatility of unlimited contact with the pathogens. The team has successfully completed large scale
choice of material offered manufacturing trials in collaboration with a textile industry partner in Delhi-
by powder metallurgy. NCR region to ensure that the large scale fabric manufacturing can be done
The company is led by Dr while maintaining its high-efficiency & affordability.
Ravi Bollina along with
Deepak Kukreti and Sasant
Nuthakki. The project was
received under the Call for
Proposal ‘Commercialisation
of Indigenous Technologies
from Indian Startup
Companies’ by TDB.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com START UP NEWS 11

IIT-H based startup designs Chronic disease
ICU ventilator- Jeevan Lite management
startup
Hyderabad-based startup five hours and is both invasive PhableCare
Aerobiosys Innovations from and non-invasive, with a raises Rs 187 Cr
the Center for Healthcare smartphone app to control the
Entrepreneurship (CfHE), device. The device has been Bengaluru headquartered
Indian Institute of designed based on the turbine- PhableCare has raised Series B
Technology (IIT) driven flow method, which funding of Rs 187 crores within
Hyderabad has come provides independence from gas one year of raising Series A. The
up with a smart round was led by Kalaari Capital
ventilation system cylinders or compressors. with participation from Aflac
named Jeevan It also comes with Ventures, Digital Horizon, Stride
Lite. The smart an integrated Ventures. Existing investors,
ventilation system nebulizer with auto Omron Ventures, SOSV, Social
is portable, cut off precise timer. Starts, and Fresco Capital also
cost-effective, Jeevan Lite features participated in the round.
IoT-enabled, all the essential Currently 3 million+ patients and
and powered 10k+ doctors and over 1000+
by lithium- modes expected from an pharmacists use PhableCare’s
ion batteries. advanced ventilation technology making it the market
It operates system in one leader in this segment. The new
uninterrupted adaptable platform. investment further bolsters
in SIMV, CMV, The device costs Rs 4 PhableCare’s rapid growth in
Adaptive and Hybrid lakh/ unit against 2021. This funding round marks
modes of ventilation for similar imported a 6x jump in PhableCare’s
devices worth Rs valuation within a short time.
10-15 lakh/ unit. The company will use this
investment to further strengthen
Pfizer INDovation Programme its full-stack and value-driven
supports breakthrough chronic care ecosystem and
healthcare innovations in India accelerate its market expansion,
customer acquisition (doctors
Atal Innovation Mission, NITI Aayog, AGNIi, Foundation for and patients), brand building,
Innovation and Technology Transfer (FITT), IIT-Delhi, Pfizer and and building new revenue
Social Alpha have come together to launch the Pfizer INDovation streams. The startup has plans
Programme to support breakthrough healthcare innovations to acquire other players through
by startups in India. Social Alpha is the core implementation strategic investments, which will
partner responsible for executing the consolidate PhableCare’s position
programme. This is Version 2.0 of in the category. The company
the Pfizer IIT-Delhi Innovation and has allocated capital and secured
IP Programme and is one of Pfizer’s additional venture debt to invest
CSR initiatives. In Version 1, Pfizer in other health-tech startups
successfully incubated 9 healthcare that can potentially create a
innovators and supported 19 IP filings. thriving healthcare eco-system
Now, in the first year of Version 2.0, through capacity and capability
three winning startups each in the expansion.
areas of Oncology and Digital Health,
will receive a grant of up to Rs 65 lakh
each for product trials, pilot studies,
and product market launches to accelerate the lab-to-market journey
of their innovation. This is one of the largest such programmes,
both by grant value and partnerships, to focus on incubating and
commercialising healthcare startups in the country.

12 POLICY AND REGULATORY NEWS BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

India calls Glenmark gets DCGI
upon Shanghai approval for Ph 1 trial of
Cooperation novel cancer molecule
Organisation
for scientific Glenmark Pharmaceuticals has announced that its subsidiary
innovations Glenmark Specialty (Glenmark) has received approval from the Indian
drug regulator, Drug Controller General of India (DCGI), to conduct
The Union Minister of State a Phase 1 clinical trial of its novel small-molecule, GRC 54276, a
(Independent Charge) Science hematopoietic progenitor kinase 1 (HPK1) inhibitor. GRC 54276 is
& Technology; Minister of State one of the many novel molecules from Glenmark’s resident Innovative
(Independent Charge) Earth Medicines Group, headed by Dr Nikhil
Sciences; MoS PMO, Personnel, Amin, Chief Scientific Officer, specialising
Public Grievances, Pensions, in the development of novel molecular
Atomic Energy and Space, entities for critical unmet medical needs.
Dr Jitendra Singh has called HPK1 is a key regulator of T cell, B cell
upon the countries of Shanghai and dendritic cell-mediated immune
Cooperation Organisation responses, which improves antitumor
(SCO) to join hands to innovate immunity by activating and priming T cells.
affordable scientific solutions GRC 54276 has shown tumour cell killing
for common challenges like ability in preclinical studies as a single
ensuring food, affordable agent and as well in combination with checkpoint inhibitors, making
healthcare and energy access for it a high-priority target in immuno-oncology. The study will evaluate
its people. Addressing the SCO the safety and tolerability of GRC 54276 as a monotherapy, and also
meeting through virtual mode in combination with checkpoint inhibitors in patients with advanced
recently, Dr Jitendra Singh solid tumours and Hodgkin’s lymphoma. Glenmark will initiate Phase
said the member countries 1 clinical trial in India by June 2022, and also plans to file an IND in the
must jointly address emerging US and Clinical Trial Applications in Europe to kick off a fully global
challenges of environmental clinical study programme.
problems like climate change
and biodiversity loss. Dr AYUSH Ministry
Jitendra Singh pointed out that announces establishment
as a result of consistent boost of Integrative Medicine Unit
to research and innovation,
India has reached third position All India Institute of Ayurveda (AIIA), the apex institute of Ayurveda in
in scientific publication as per India under the Ministry of AYUSH, and Vardhman Mahavir Medical
National Science Foundation College and Safdarjung Hospital (VMMC & SJ Hospital) have signed a
(NSF) database. The country Memorandum of Understanding (MoU) to develop a unique centre of
has featured within the top 50
innovative economies globally excellence (CoE) model of Integrative
(at 46th rank), as per Global Health Facility in the country for
Innovation Index (GII) and it tertiary care. As per the agreement,
has also reached third position both AIIA and VMMC & SJ Hospital
in terms of number of PhDs, will jointly work to treat patients
in size of Higher Education using the best of both Ayurveda
System; as well as in terms of and Modern Medicine. Under the
number of startups. agreement, the infrastructural space
and other requisites to run the centre
on a day-to-day basis will be provided
by VMMC & SJ Hospital, whereas the technical support including
manpower, technical infrastructure, and running of the centre will be
managed by AIIA.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com POLICY AND REGULATORY NEWS 13

Govt invests Rs 200 Cr in development of 2 new vaccines

Technology Development Board commercialisation of the two cGMP facility in Bhubaneswar, in
(TDB), Ministry of Science novel vaccines. The company compliance with the latest global
& Technology is supporting aims to set up a state-of-the-art standards, for manufacturing
Hyderabad-based startup Sapigen Intranasal COVID-19 Vaccine
Biologix for the development and and (RTS, S) Malaria Vaccine
commercialisation of two novel initially and later expand the
vaccines – Intranasal COVID-19 product portfolio by adding other
Vaccine and RTS, S Malaria vaccines. The company intends
Vaccine. Under the agreement to produce 100 million doses/
signed, TDB and Bharat Biotech annum of intranasal COVID-19
have pledged the support of vaccine by April 2023 and 15
Rs 200 crore each to create a million doses/ annum RTS, S
continuous corpus of Rs 400 Malaria vaccine by the end of
crore for the development and April 2025.

HP signs MoU with NIPER DBT unveils data-driven
as knowledge partner for
medical devices park research to eradicate

Chief Minister Jai Ram Thakur has announced that TB - ‘Dare2eraD TB’
the Himachal Pradesh (HP) Government has signed a
Memorandum of Understanding (MoU) with National The Union Minister of State (Independent
Institute of Pharmaceutical Education & Research Charge) Science & Technology; Minister of State
(NIPER), Mohali as Knowledge Partner for upcoming (Independent Charge) Earth Sciences; MoS
Medical Devices Park, Nalagarh in Solan district. This PMO, Personnel, Public Grievances, Pensions,
MoU was approved by the Board of Members from Atomic Energy and Space, Dr Jitendra Singh
the Department of Pharmaceuticals, Government recently announced the launch of Data-Driven
of India (GoI). HPSIDC is the State Implementing Research to Eradicate TB- Dare2eraD TB by the
Agency for conception, development and execution Department of Biotechnology (DBT). Dare2eraD
of Medical Devices Park. NIPER Mohali will establish TB will be the umbrella TB programme of
a Centre for Excellence in the Medical Devices Park DBT comprising of the Indian Tuberculosis
that will enable Industry-Academia linkage. State Genomic Surveillance Consortium; InTBK Hub-
Planning Department has sanctioned Rs 74.95 crore Indian TB Knowledge Hub- Webinar Series;
to the State Implementing Agency for development of and Host Directed therapies against TB and
this park & the Department of Pharmaceuticals, GoI develop an evidence-based regimen for treating
would soon release the first installment worth Rs 30 extra-pulmonary tuberculosis. The Indian
crore of grant-in aid. Tuberculosis Genomic Surveillance Consortium
(InTGS) is proposed on lines of the Indian
SARS-CoV-2 Genomic Consortia (INSACOG).
The InTBK Hub- Indian TB Knowledge Hub will
be a webinar series that will create academia-
industry connections to discuss challenges
and exchange ideas and carry forward open
innovations between all TB stakeholders.

14 FINANCE NEWS BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

Akums Drugs & Pharmaceuticals buys Ankur
Drugs’ HP plant to boost production capacity

Akums Drugs & in Nalagarh in Solan, Himachal total capacity further. This
Pharmaceuticals, Pradesh (HP), Akums is trying expansion is a step towards
Haridwar-based to bridge some capacity gaps in achieving the goal of 20
contract manufacturing the pharma industry. In 2021, per cent market share.
pharmaceutical company, the supplies by Akums made The operations at Kotdwar
has recently acquired a up approximately 12 per cent plant have begun recently,
facility from Ankur Drugs of the total market. With this while the new plant in
and Pharmaceuticals. new facility acquisition in the Himachal Pradesh is likely
The facility acquired by state of Himachal Pradesh and to start its operations by
Akums is one of largest drug previous acquisition in Kotdwar, December 2022. Apart from
manufacturing facilities in the Uttarakhand, in August 2021, these changes, Akums had also
country. With this acquisition the company has bolstered its acquired three API facilities
Akums’ will boost its production near Chandigarh in January
capacities for general oral tablets 2021, all of which contribute to
and oral liquids. The planned building its capacity and efficient
capacities of the new facility are backward-integrated supply chain
6 billion units of tablets and 90 to strengthen its market leader
million units of oral liquids per position in India, since Akums
annum. This facility is most likely manufactures approximately 12
to be fully operational by the end per cent of all drugs consumed in
of 2022. With this new facility the country.

Suven Pharma acquires Alembic Pharma
Casper Pharma for Rs 155 Cr
picks 100% stake in
The Board of Directors of Suven Pharmaceuticals Limited
(SPL) has approved the investments by way of purchase Aleor Dermaceuticals
of entire (100 per cent) share capital from the existing
shareholders of Casper Pharma Private Limited (CPPL), a Vadodara-based Alembic Pharmaceuticals
Hyderabad based SEZ company engaged in formulations has acquired the balance 40 per
business. Post purchase of shares, the target entity cent stake in Aleor Dermaceuticals
would become a wholly owned subsidiary of SPL. Cash from its joint-venture (JV) Partner
Orbicular Pharmaceutical Technologies
consideration of $20.5 million (Orbicular) to strengthen its skin-
based on the present exchange related manufacturing and marketing
rate equivalent to around Rs 155 footprint. The Board of Directors of Aleor
crore will be paid to the sellers has been reconstituted with Orbicular
of the shares in the target entity. nominees resigning from the Board. The
The present manufacturing amalgamation will integrate business
facility of Casper Pharma has an operations and provide impetus to
installed capacity of 1.2 billion the existing portfolio of Alembic. The
tablets/ capsules. The company acquisition augers well with the strategic
is ready for USFDA inspection which is expected to happen planning and growth trajectory set by the
within the next 6 months’ time frame. The unit is yet to company to capture a higher market share
reach its commercially viable operations. The objective of in various segments of its pharmaceutical
this acquisition is to acquire formulations facility of Casper business. The combined entity will have
Pharma and to engage in manufacturing and supplying solid a bigger portfolio of products and direct
oral dosage formulations including tablets, capsules and access to markets, which will strengthen
liquid oral products through the contractual arrangement overall capabilities to serve more
with customers for USA and other regulated markets. efficiently across different therapies, both
overseas as well as domestic.



16 COMPANY NEWS BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

Sun Pharma brings SRL Diagnostics,
version of antidepressant
Vortioxetine in India Skye Air Mobility

Sun Pharmaceutical Industries has announced that one revolutionise logistics
of its wholly-owned subsidiaries has entered into an
exclusive patent licensing agreement with Denmark- in diagnostics
based H Lundbeck (Lundbeck) to market and distribute
its version of Vortioxetine in India under the brand name, Skye Air Mobility, a drone delivery logistics
VORTIDIF. The territory of the licensing agreement will provider, has signed a long-term agreement
only cover India. Vortioxetine is a novel antidepressant with SRL Diagnostics. The partnership
with multimodal activity, which is approved to treat between Skye Air Mobility & SRL Diagnostics
Major Depressive Disorder (MDD) in adults. The product is expected to revolutionise logistics in the
is approved in over 80 countries, including the US, the diagnostics industry. This partnership is
EU, Canada and Australia. MDD is one of the leading unique in the pathology sector since it will
causes of disability, affecting approximately 246 million leverage drone delivery technology to create
people globally and 35 million people in India. MDD is a faster supply chain for collecting samples
characterised by pronounced changes in mood coupled and transporting them to labs in Gurugram
with distinct psychological and vegetative changes, and Mumbai.
including sleep, appetite disturbance, subjective fatigue, The duo is
loss of motivation and drive, ruminative feelings of guilt conducting
and despair, problems maintaining mental focus, and BVLOS drone
suicidal thinking and behaviour. delivery trial
flights in
designated
green zones
in Gurugram and Mumbai regions. This will
help them build efficiencies for specialised
and super-specialised tests that are typically
performed only at SRL’s Global Reference
Laboratories. Since the time taken for sample
transfer is cut down, the company will have
better temperature control for samples,
especially during the summer months.

Dr. Reddy’s announces introduction of
medical cannabis products in Germany

Hyderabad-based Dr. Reddy’s access to medicinal cannabis on the process of reimbursement
Laboratories and MediCane products, from MediCane, under by health insurance. This launch
Health Inc. have announced its own brand, with the support marks MediCane’s entry into
the launch of their therapeutic of a field team, specialised the pharmaceutical sector of a
cannabis product in Germany. and able to provide healthcare major European market. For Dr.
Under a collaboration between Dr. professionals training on the use Reddy’s, this launch strengthens
Reddy’s and MediCane that began of the products as well as advice its presence in the growing
in 2021, MediCane will supply German medical cannabis market,
medical cannabis products to Dr. a presence already strengthened
Reddy’s from its EU GMP-certified since the company’s recent
facilities based in Portugal, while acquisition of Nimbus Health
providing logistical and regulatory GmbH, specialising in the
support. As the exclusive distribution, registration, sale
distributor of the products in and the commercialisation of
Germany, Dr. Reddy’s will provide therapeutic cannabis.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com COMPANY NEWS 17

US-based Enveda Bayer plans
Biosciences opens lead to set up 27
optimisation lab in Hyderabad telemedicine
centres across
US-based Enveda Biosciences, a software, among other state- 8 states in
leading biotechnology company of-the-art synthetic chemistry India
harnessing the power of nature’s technologies used in the lead
chemistry, is opening a lead optimisation cycle. The company German firm Bayer will be
optimisation laboratory in expects to move into the new setting up 27 telemedicine
Genome Valley, Hyderabad laboratory by the end of 2022. centres in 12 districts across
which is home to more than 200 Enveda can expand its space 8 states in India over the next
life science and pharmaceutical in Hyderabad to accommodate two years, through Bayer
companies including Novartis and nearly triple its current workforce. Foundation India. The centres
Lonza. Enveda’s 24,000-square- The company is also building out being set up in partnership with
foot space will bolster the an advanced drug discovery and RxDx Healthcare and Piramal
company’s growing workforce development centre in the heart Swasthya, the public health
in India and enable it to of Boulder, Colorado in the US. arm of Piramal Foundation, are
more efficiently optimise lead The 60,000-square-foot facility in line with the core values of
compounds to identify clinical will significantly expand Enveda’s Bayer to ensure timely access
drug candidates. The Genome capacity to build a high-resolution to quality healthcare, build
Valley laboratory will house chemical map of the natural world local health capacities, and
imaging instruments, automated and identify new high-potential support local innovations. The
liquid handlers, and analysis drug leads from it. key objectives of this endeavour
are to establish a telehealth
Cadila Pharma launches novel facility in the identified
three-dose rabies vaccine, ThRabis states of Bihar, Chhattisgarh,
Jharkhand, Karnataka, Gujarat,
Ahmedabad-based Cadila Pharmaceuticals has developed a novel Uttar Pradesh, Maharashtra,
three-dose recombinant nano-particle based rabies G protein & Madhya Pradesh to provide
vaccine. A campaign has also been launched under the name ‘One, complete healthcare solutions
Two, Three. Rabies Free.’ The vaccine - ThRabis is prepared by using via telehealth and conduct
Virus-Like Particle technology (VLP). The VLPs self-assemble from training and awareness
this recombinant G protein which is produced from genes cloned into sessions on health, hygiene and
baculovirus expression vectors and expressed in Spodoptera frugiperda nutrition. In addition, medical
(Sf9) insect cells. The vaccine generates antibodies against rabies G camps will be conducted at
protein, which leads to virus neutralisation, as well as prevents virus regular intervals to create
attachment to the cell to confer protection against rabies. It is estimated awareness on specific health
that globally, rabies kills 59,000 animal bite victims every year, mainly in aspects like breast cancer,
Asia and Africa. Over 20,000 people die in India alone, mainly because diabetes, dermatology. RxDx
many animal bite victims do not complete the full course of the available Healthcare & Piramal Swasthya
vaccine. bring expertise in running
telemedicine centres located in
Primary Health Centres (PHCs)
of the targeted districts.



Evolution of Scaling Up with Corning®
andFalcon® Cell Culture Flasks

From 12.5 cm2 to 1720 cm2 Corning Scale-up Flasks

Corning offers the largest selection of traditional

one that best meets your needs.

Falcon Corning Corning Falcon Corning Falcon Falcon 3-layer Falcon 5-layer Corning
Flask with Flask with U-Shaped Canted U-Shaped Rectangular Multi-Flask HYPERFlask®
Vented Cap Neck Flask Multi-Flask
Vented Canted Angled Flask
Cap Neck Flask Neck Flask

12.5 cm2 75 cm2 175 cm2 525 cm2 875 cm2 1720 cm2

Corning HYPERFlask Cell Culture Vessels Falcon Cell Culture Multi-Flask

10 interconnected polystyrene growth surfaces An easier, more productive way to culture cells
(Cat. Nos. 10020, 10030, 10024, and 10034) (Cat. Nos. 353143 and 353144)

The Corning HYPERFlask cell culture vessel Falcon Cell Culture Multi-Flasks enable
offers 1720 cm2 growth area in the footprint you to grow more cells faster and
of a traditional 175 cm2 flask. The Corning easier, thereby making your cell culture
High Yield PERformance (HYPER) technology workflow more productive. The tissue
of this polystyrene flask utilizes a multi- culture-treated Falcon Multi-Flasks are
layered gas permeable Corning CellBIND® available in 3- or 5-layer formats that
surface for superior cell attachment and provide 525 cm2 or 875 cm2 cell growth
growth. surface area. They can be used with
a wide range of liquid volumes (up to
Successfully used for cell propagation (adherent and 50 mL/layer).
non-adherent), protein production, virus production,
and transfections Can be used for viral production as well as scale up of cells

The next generation HYPER technology lets you grow large Even distribution of media across all layers for homogeneous
quantities of adherent cells in a compact space cell population

Reduces processing time and incubator storage space by Ability to mix in the Falcon Multi-Flask saves time and
handling one flask as compared to 10 traditional 175 cm2 reduces risk of contamination
flasks
Flexible design lets you pour or aspirate/recover cells using
Scalable to Corning CellSTACK® culture chambers a pipet

Cat. No. Description Surface Qty/Pk Qty/Cs Consistent surface treatments for predictable scale-up
10024 HYPERFlask vessel Corning CellBIND 4 24
10030 HYPERFlask M vessel Corning CellBIND 1 4 Manufactured in compliance to cGMP standards
10020 HYPERFlask M vessel Corning CellBIND 4 4
10034 HYPERFlask M vessel Corning CellBIND 4 24 Cat. No. Description Surface Area Cap Style Qty/Cs
353143 3-layer, TC-treated 525 cm2 Vented 12
353144 5-layer, TC-treated 875 cm2 Vented 8

India t 91 124 4604000 f 91 124 4604099 Check out the selection guide [email protected]

20 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

Indian biopharma industry

HITS Rs 33K Cr WITH

13% GROWTH
IN 2020-21

Amidst the pandemic, the Indian Biopharma In the import of Hormones, Prostaglandins,
Industry, with over 300 companies, has Thromboxanes and Leukotrienes, Natural or Reproduced
witnessed a good growth of 13 per cent, by Synthesis; Derivatives and Structural Unit space,
2 per cent less than the previous year’s Indian companies have registered negative growth of
15 per cent growth rate. This growth 1.34 per cent with sales revenue of Rs 2,186 crore in
was largely driven by performance of the Indian 2020-21 as against Rs 2,215 crore recorded in 2019-20.
biopharma companies which have done very well
as against multinational companies. As a result, the According to All Indian Origin Chemists &
Indian Biopharma Industry has crossed the Rs 33,000 Distributors (AIOCD) Pharmasofttech AWACS Pvt.
crore mark for the year 2020-21 over the previous Ltd, the overall Indian domestic biopharma (insulin,
year’s figure of Rs 29,176 crore. The Indian Biopharma vaccines, hormones, and blood products) market
industry, comprising hormones, insulin, blood products registered less than one per cent growth in 2020-21
and vaccines recorded a sales revenue of Rs 33,067 as against 10 per cent growth registered in 20219-10
crore for the year 2020-21. with the vaccine (out of pocket) market witnessing a
negative growth of 2.7 per cent, the insulin market
According to the Department of Commerce, witnessed 3.9 per cent growth, blood products
government of India, the Indian vaccine players have recorded -1.4 per cent and hormones market recoded
increased their export share in 2020-21 to Rs 6492 1.4 per cent growth in 2020-21. Novo Nordisk India
crore as against Rs 5723 crore reported in 2019-20 Pvt Ltd is leading the insulin market in India with sales
registering a growth of 13.42 per cent. In 2018-19 India revenue of Rs 1,467 crore in 2020-21.
exported Rs 4453 crore worth human vaccines.
In the out of pocket market for human vaccine
In the veterinary vaccine space too, Indian Glaxosmithkline Pharmaceuticals Ltd. is leading with
companies have performed well with export figures sales of Rs 633 crore, followed by Sanofi India Ltd (Rs
soaring from Rs 233 crore in 2019-20 to Rs 253 crore in 432 crore), Serum Institute of India Ltd (Rs 141 crore),
2020-21. Pfizer Ltd (Rs 132 crore), Biological E Ltd (Rs 123 crore)
and Bharat Serums & Vaccines Ltd (Rs 105 crore). In the
Indian companies have increased their export share hormones market, Macleods Pharmaceuticals Pvt Ltd
of insulin injection in 2020-21 to Rs 372 crore from Rs is leading the market with a sales revenue of Rs 393
247 crore recorded in 2019-20 with growth of 50.47 per crore, followed by Abbott India Ltd. at Rs 367 crore,
cent. Similarly, India has increased export of insulin and Glaxosmithkline Pharmaceuticals Rs 323 crore, Pfizer
its salts in 2020-21 to Rs 229 crore from Rs 200 crore in Ltd Rs 301 crore and Zydus Lifesciences (formerly Zydus
2019-20 registering 14.62 per cent growth. At the same Cadila) Rs 270 crore.
time, during 2020-21, India imported Rs 1,538 crore
worth insulin injection, as against Rs 1,328 crore the In blood products there are over 100 companies
previous year registering a growth of 15.84 per cent. doing business, while in the hormones space, too, there
are about 140 companies in the business. In the insulin
Though India is a leading vaccine manufacturer, and vaccines space the number of companies are less
companies still imported Rs 2,628 crore worth vaccines than 20 and 35, respectively. In all these biological
in 2020-21 as against Rs 2,804 crore imported in 2019- segments, foreign multinational companies are leading
20, registering a decline of 6.25 per cent. However, the domestic market. While Indian companies do have
in the veterinary vaccine space India has increased its some presence, they need to do a lot of heavy lifting to
import figures by 8.38 per cent in 2020-21 to Rs 253 catch up to the foreign biggies.
crore against Rs 233 crore reported in 2019-20.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 21

SERUM INSTITUTE
OF INDIA LTD

CONTINUES TO LEAD THE
INDIAN BIOPHARMACEUTICAL
INDUSTRY AT No 1 POSITION

Pune-based Serum Institute of India Ltd continues to lead the Indian Biopharmaceutical
Industry with a revenue of Rs 7201 crore for the year 2020-21 followed by Bangalore-based
Biocon Ltd with Rs 5136 crore and Hyderabad-based Sanofi Healthcare India Pvt Ltd with
Rs 1739 crore respectively.

Top 3 Biopharma Top 10 Biopharma Top 20 Biopharma
companies contribute companies contribute companies contribute

45%to of the total 73%to of the total 90%to of the total
Biopharma Industry Biopharma Industry Biopharma Industry

BioSpectrum Top 20 BioPharma Companies 2021*

Revenue Revenue

Sr. Company in in % Category Location Region
No 2020-21 2019-20 growth

(in Crore) (in Crore)

1 Serum Institute of India Ltd. 7201 5014 44 India Pune West
2 Biocon Ltd. 14 India Bengaluru South
3 Sanofi Healthcare India Pvt. Ltd. 5136 4487 -1 MNC Hyderabad South
4 Novo Nordisk India Pvt. Ltd. 0 MNC Bengaluru South
5 Bharat Biotech International Ltd. 1,739 1,761 35 India Hyderabad South
6 Biological E Ltd. 36 India Hyderabad South
7 Reliance Life Science Pvt. Ltd. 1467 1465 38 India Mumbai West
8 Sanofi India Ltd. 5 MNC Mumbai West
9 Intas Pharmaceuticals Ltd. 1439 1066 26 India Ahmedabad West
10 Glaxosmithkline Pharmaceuticals Ltd. -9 MNC Mumbai West
11 Bharat Serums & Vaccines Ltd. 1418 1040 3 India Mumbai West
12 Indian Immunologicals Ltd. -9 India Hyderabad South
13 Zydus Lifesciences Ltd. 1404 1018 26 India Ahmedabad West
14 Concord Biotech Ltd. 13 India Ahmedabad West
15 Pfizer Ltd. 1101 1052 4 MNC Mumbai West
16 Macleods Pharmaceuticals Pvt. Ltd. 4 India Mumbai West
17 Lupin Ltd. 1071 850 4 India Mumbai West
18 Abbott India Ltd. 3 MNC Mumbai West
19 Venkateshwara Hatcheries Pvt. Ltd. (Vaccines) 966 1065 3 India West
20 Wockhardt Ltd. 10 India Pune West
942 917 Mumbai

747 820

646 513

616 543

538 519

488 471

442 424

406 395

308 299

231 210

* We have not covered some of the Biopharma companies as they are unable to participate in the BioSpectrum Survey 2020-21

22 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

BioSpectrum Top 21-55 BioPharma Companies 2021*

Revenue Revenue

Sr. Company in in % Category Location Region
No 2020-21 2019-20 growth
New Delhi North
(in Crore) (in Crore) Mumbai West
West
21 Panacea Biotec Ltd 228 140 62 India Pune North
Gurugram West
22 Sun Pharma Laboratories Ltd. 213 193 10 India Ahmedabad West
Mumbai West
23 Fresenius Kabi India Pvt Ltd 205 182 12 MNC Mumbai West
Ahmedabad
24 Eli Lilly and Company (India) Pvt. Ltd. 172 183 -6 MNC

25 Hester Biosciences Limited 162 154 5 India

26 Abbott Healthcare Pvt. Ltd 145 157 -8 MNC

27 MSD Pharmaceuticals Private Ltd. 99 85 17 MNC

28 La Renon Healthcare Pvt. Ltd. 90 92 -2 India

29 Bharat Immunologicals and 87 68 28 India Bulandshahr North
Biologicals Corporation Ltd

30 Haffkine Bio-Pharmaceutical 84 126 -33 India Mumbai West
Corporation Limited.

31 Globion India Pvt Ltd 80 78 3 India Coimbatore South

31 Indovax Private Limited 80 74 7 India Gurugram North

32 Biovet Private Limited 75 111 -32 India Bengaluru South

33 Dr. Reddys Laboratories Ltd 71 79 -10 India Hyderabad South

34 Ranbaxy Laboratories Ltd 68 57 20 India Gurugram North

35 Brilliant Bio Pharma Private Limited  67 166 -60 India Hyderabad South

36 Mankind Pharmaceuticals Ltd. 60 58 3 India New Delhi North

37 Micro Labs Ltd 58 60 -3 India Bengaluru South

38 Paviour Pharmaceuticals Pvt Ltd 51 44 17 India New Delhi North

39 RPG Life Sciences Ltd. 50 30 70 India Mumbai West

39 Zoetis India Limited 50 45 11 MNC Mumbai West

39 Zuventus Healthcare Ltd 50 56 -12 India Mumbai West

40 Samarth Life Sciences Pvt Ltd 44 43 2 India Mumbai West

40 Cipla Ltd. 44 49 -12 India Mumbai West

41 Cadila Pharmaceuticals Ltd 41 17 136 India Ahmedabad West

42 Alniche Life Sciences Pvt. Ltd 38 37 5 India New Delhi North

43 Wallace Pharmaceuticals Ltd. 31 29 8 India Goa West

44 Boehringer Ingelheim India Pvt Ltd. 30 23 30 MNC Mumbai West

45 Green Signal Bio Pharma Pvt Ltd 28 13 109 India Chennai South

46 Alkem Laboratories Ltd. 26 25 1 India Mumbai West

47 Juggat Pharma Ltd 25 24 3 India Mysuru South

48 AstraZeneca Pharma India Ltd 24 21 12 MNC Bengaluru South

49 Jagsonpal Pharmaceuticals Ltd 21 19 8 India New Delhi North

50 Ozone Pharmaceuticals Ltd 20 27 -24 India New Delhi North

51 Neon Laboratories Ltd 19 19 -2 India Mumbai West

51 Mercury Healthcare Pvt Ltd 19 18 3 India Mumbai West

52 Shreya Life Sciences Pvt. Ltd 16 36 -56 India Mumbai West

53 Oaknet Healthcare Pvt Ltd 15 17 -12 India Bengaluru South

53 Corona Remedies Private Limited 15 19 -21 India Ahmedabad West

53 Aristo Pharmaceuticals Pvt.Ltd 15 14 4 India Mumbai West

54 Roche Products (India) Pvt. Ltd. 13 9 33 MNC Mumbai West

55 Ferring Pharmaceuticals Pvt Ltd 12 23 -48 MNC Mumbai West

55 FDC Ltd. 12 11 5 MNC Mumbai West

55 Raptakos, Brett & Co. Ltd. 12 16 -25 India Mumbai West

* We have not covered some of the Biopharma companies as they are unable to participate in the BioSpectrum Survey 2020-21

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 23

Indian companies contribute 78% of the total biopharma Industry while remaining 22% by the MNC firms.

BioSpectrum Top 10 Indian BioPharma Companies 2021*

Sr. Company Revenue in Revenue in % Category Region
No 2020-21 2019-20 growth
(in crore) (in crore) Pune West
1 Serum Institute of India Ltd. 7201 5014 44 Bengaluru South
2 Biocon Ltd. 5136 4487 14 Hyderabad South
3 Bharat Biotech International Ltd. 1439 1066 35 Hyderabad South
4 Biological E Ltd. 36 Mumbai West
5 Reliance Life Science Pvt. Ltd. 1418 1040 38 Ahmedabad West
6 Intas Pharmaceuticals Ltd. 26 Mumbai West
7 Bharat Serums & Vaccines Ltd. 1404 1018 3 Hyderabad South
8 Indian Immunologicals Ltd. 1071 850 -9 Ahmedabad West
9 Zydus Lifesciences Ltd. 942 917 26 Ahmedabad West
10 Concord Biotech Ltd. 13
747 820 Region
646 513
616 543 South
South
BioSpectrum Top 10 MNC BioPharma Companies 2021* West
West
Sr. Company Revenue in Revenue in % Category West
No 2020-21 2019-20 growth West
(in crore) (in crore) Hyderabad West
1 Sanofi Healthcare India Pvt. Ltd. 1,739 1,761 -1 Bengaluru North
2 Novo Nordisk India Pvt. Ltd. 1467 1465 0 Mumbai West
3 Sanofi India Ltd. 1101 1052 5 Mumbai West
4 Glaxosmithkline Pharmaceuticals Ltd. -9 Mumbai
5 Pfizer Ltd. 966 1065 4 Mumbai
6 Abbott India Ltd. 538 519 3
7 Fresenius Kabi India Pvt. Ltd. 406 395 12 Pune
8 Eli Lilly and Company (India) Pvt. Ltd. -6 Gurugram
9 Abbott Healthcare Pvt. Ltd. 205 182 -8 Mumbai
10 MSD Pharmaceuticals Pvt. Ltd. 172 183 17 Mumbai

145 157
99 85

* We have not covered some of the Biopharma companies as they are unable to participate in the BioSpectrum Survey 2020-21

BIOSPECTRUM BIOPHARMA
SURVEY AND METHODOLOGY
BIOPHARMA COMPANIES

BioSpectrum India, a leading B2B media companies (both MNCs and domestic players) based
platform in Lifesciences space since 2003, on their achievements in the past financial years.
re-launched its ranking special edition in
June 2019 after a gap of 2 years. We have A detailed questionnaire (survey form) was sent
delayed this survey and the ranking exercise to the companies in biologicals space to capture the
in 2021 due to COVID-19, as companies were given needed information for the analysis. This was done
an extended period to submit their financial returns during October 2021 to March 2022 (Sales revenues of
till December 2021. In this survey we looked at only all the companies are in Rs Crore). Companies shared
the Biopharma Industry with companies specialising information with us to the extent it was possible by
in Biologics/Blood products/ Recombinant products/ them. We have collected information about listed
mAbs/ Vaccines/ Insulin. We have highlighted the companies from stock exchange, financial agencies and
speaking with industry experts as well.

#The revenues considered for the analysis are biologicals sales and service figures. In several cases, where revenue figures were not available, estimates were arrived at in
discussion with industry experts.
#For all the ranking purposes, we have taken the biopharma business only into consideration. Wherever ‘Revenue is mentioned, it means sales turnover from the
biopharma division. Therefore, revenue wherever mentioned is not necessarily the total sales turnover of the company.

24 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

Western region continues to dominate the biopharma industry with contribution of
60% followed by Southern region with 38% and 2% coming from Northern region.

BioSpectrum Top 10 Biopharma Companies in West

Sr. Company Revenue in Revenue in % Category Region
No 2020-21 2019-20 growth
(in crore) (in crore) India Pune
1 Serum Institute of India Ltd. 7201 5014 44 India Mumbai
2 Reliance Life Science Pvt. Ltd. 1404 1018 38 MNC Mumbai
3 Sanofi India Ltd. 1101 1052 5 India Ahmedabad
4 Intas Pharmaceuticals Ltd. 26 MNC Mumbai
5 Glaxosmithkline Pharmaceuticals Ltd. 1071 850 -9 India Mumbai
6 Bharat Serums & Vaccines Ltd. 966 1065 3 India Ahmedabad
7 Zydus Lifesciences Ltd. 942 917 26 India Ahmedabad
8 Concord Biotech Ltd. 13 MNC Mumbai
9 Pfizer Ltd. 646 513 4 India Mumbai
10 Macleods Pharmaceuticals Pvt. Ltd. 616 543 4

538 519
488 471

BioSpectrum Top 10 Biopharma Companies in South

Sr. Company Revenue in Revenue in % Category Region
No 2020-21 2019-20 growth
(in crore) (in crore) India Bengaluru
1 Biocon Ltd. 5136 4487 14 MNC Hyderabad
2 Sanofi Healthcare India Pvt. Ltd. 1739 1761 -1 MNC Bengaluru
3 Novo Nordisk India Pvt. Ltd. 1467 1465 0 India Hyderabad
4 Bharat Biotech International Ltd. 35 India Hyderabad
5 Biological E Ltd. 1439 1066 36 India Hyderabad
6 Indian Immunologicals Ltd. 1418 1040 -9 India Coimbatore
7 Globion India Pvt. Ltd. 3 India Bengaluru
8 Biovet Pvt. Ltd. 747 820 -32 India Hyderabad
9 Dr. Reddys Laboratories Ltd. 80 78 -10 India Hyderabad
10 Brilliant Bio Pharma Pvt. Ltd. 75 111 -60

71 79
67 166

BioSpectrum Top 10 Biopharma Companies in North

Sr. Company Revenue in Revenue in % Category Region
No 2020-21 2019-20 growth
(in crore) (in crore) India New Delhi
1 Panacea Biotec Ltd. 62 MNC Gurugram
228 140 -6
2 Eli Lilly and Company (India) Pvt. Ltd. India Bulandshahr
172 183
India Gurugram
3 Bharat Immunologicals and 87 68 28 India Gurugram
Biologicals Corporation Ltd. India New Delhi
India New Delhi
4 Indovax Pvt. Ltd. 80 74 7 India New Delhi
68 57 20 India New Delhi
5 Ranbaxy Laboratories Ltd. 60 58 3 India New Delhi
51 44 17
6 Mankind Pharmaceuticals Ltd. 38 37 5
21 19 8
7 Paviour Pharmaceuticals Pvt. Ltd. 20 27 -24

8 Alniche Life Sciences Pvt. Ltd.

9 Jagsonpal Pharmaceuticals Ltd.

10 Ozone Pharmaceuticals Ltd.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 25

01 SERUM INSTITUTE OF INDIA LTD

REVENUE PURSUING EXCELLENCE

₹7201 crore Pune-based vaccine manufacturer Serum Institute of India (SII)
recorded a revenue of Rs 7201 crore during FY 20-21, exhibiting
DR. CYRUS S. POONAWALLA a growth of 44 per cent in comparison to the revenue
generation of Rs 5014 crore in FY 19-20.
Chairman and Managing Director At the beginning of FY 20-21, SII announced its partnership
with the University of Oxford in the UK for the trial of its COVID-19 vaccine
ADAR POONAWALLA candidate Covishield, in coordination with the Indian Council of Medical
Research (ICMR) and AstraZeneca. In the later months, the company
Chief Executive Officer entered into a landmark partnership with Gavi, The Vaccine Alliance and
the Bill & Melinda Gates Foundation, to accelerate the manufacture and
delivery of up to 100 million doses of COVID-19 vaccines for India and low-
and middle-income countries (LMICs).
According to the government’s vaccine administration data, more
than 150 crore doses of Covishield have been administered in India so far.
Very recently, a book has been launched in the market chronicling the
journey of SII’s COVID-19 vaccine Covishield. The coffee table book ‘The
Shield: Covishield’ has been penned by Prakash Kumar Singh, Director,
Government and Regulatory Affairs at Serum Institute.
During 2020, SII also collaborated with US-based Novavax for
manufacturing the antigen component of NVX CoV2373, Novavax’ COVID
19 vaccine candidate. ABEC, a leading global provider of integrated
solutions and services for biopharmaceutical manufacturing based in
the US, supported SII by delivering six 4,000L CSR bioreactors for the
manufacturing of Novavax’ COVID-19 vaccine candidate, NVX CoV2373.
Meanwhile, the company started conducting phase III clinical trial
of BCG vaccine candidate VPM1002 to evaluate its ability in reducing
infection and severe disease outcomes of COVID-19, with support from
the National Biopharma Mission.
Later in the year, International AIDS Vaccine Initiative (IAVI) and
Serum Institute of India announced an agreement with Merck, a leading
science and technology company, to develop SARS-CoV-2 neutralising
monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research
as innovative interventions to address the COVID-19 pandemic.
UK-based SpyBiotech further signed an exclusive global licensing
agreement with SII for the development of a novel virus-like-particle
(VLP) vaccine targeting COVID-19 with clinical trials being initiated in
Australia.
Simultaneously, the company also started working with US-based
Codagenix for the phase I trial of a single-dose intranasal, live attenuated
vaccine against SARS-CoV-2, which was shown to be safe and efficacious
in preclinical animal studies.
Further strengthening its fight against COVID-19, SII partnered
with Dynavax Technologies Corporation for the Phase 1/2 clinical trial
evaluating a vaccine candidate adjuvanted with CpG 1018 to prevent
COVID-19.
In addition, SII launched India’s first indigenously developed
pneumococcal vaccine – PNEUMOSIL, developed through a collaboration
spanning over a decade among Serum Institute of India, PATH and Bill
and Melinda Gates foundation.

26 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

02 BIOCON LTD

REVENUE FOCUSING ON EXPANSION

₹5136 crore Bengaluru-based biopharmaceutical company Biocon registered
a revenue of Rs 5136 crore during FY 20-21 in the biopharma
DR KIRAN space, exhibiting a growth of 14 per cent in comparison to the
MAZUMDAR-SHAW revenue generation of Rs 4487 crore in FY 19-20.
The generics vertical delivered 6 per cent year-on-year
Executive Chairperson growth in FY 20-21 primarily driven by the US formulations business
and modest growth in the API business. Generics Formulations
achieved a key milestone with the launch of Tacrolimus capsules, an
immunosuppressant used to treat organ transplant patients, in the US.
The company also entered new partnerships to expand its commercial
footprint to Singapore, Thailand and Brazil.
On the other hand, the biosimilars business revenue recorded a
growth of 21 per cent. The company commercialised its third biosimilar,
Insulin Glargine, in the US and obtained regulatory approvals for key
biosimilars Bevacizumab and Insulin Aspart in the European Union.
With the pandemic overwhelmed healthcare systems globally,
chronic diseases took a backseat as budgets and resources were diverted
to tackle COVID-19. This and other COVID-19 related challenges affected
the growth trajectory of Biocon’s biosimilars business.
Realising the acute need for an effective treatment for people
hospitalised with COVID-19 and those at risk of developing severe illness,
the company repurposed its ‘first in class’ anti-CD6 monoclonal antibody,
Itolizumab, which has a unique ‘mechanism of action’ in controlling
cytokine release syndrome (CRS). The Drugs Controller General of India
(DCGI) granted Restricted Emergency Use approval to Itolizumab in July
2020, to treat CRS in patients experiencing moderate to severe acute
respiratory distress syndrome (ARDS) due to COVID-19. The company is
gathering additional data as part of the Phase 4 post marketing study
for Itolizumab, which will further validate the potential of this therapy in
COVID-19.
US-based Equillium reported encouraging developments on the
clinical advancement of Itolizumab in treating acute graft-versus-host
disease, lupus, lupus nephritis, and uncontrolled asthma. Further,
Bicara Therapeutics, based in the US, started operating as a standalone
company under an independent management team in FY 20-21 after
Biocon ceded control to its Board and Management.
The FY 20-21 also saw Tata Capital Growth Fund investing Rs 225 crore
in Biocon Biologics for an equity stake of 0.85 per cent. Biocon Biologics
also announced a global collaboration agreement between its subsidiary
Biocon Sdn. Bhd., Malaysia and Voluntis to develop and distribute
innovative digital therapeutics supporting people with diabetes on
biologics therapy. The agreement makes Biocon Biologics one of the first
insulins companies to offer a US Food and Drug Administration-cleared
and CE-marked, highly validated digital therapeutic product, Insulia, to
Type 2 diabetes patients, across several markets in the world.
Biocon Biologics further signed an agreement with the Clinton Health
Access Initiative (CHAI) during FY 20-21, to expand access to lifesaving
cancer biosimilars in over 30 countries in Africa and Asia as a part of the
Cancer Access Partnership.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 27

03 SANOFI HEALTHCARE
INDIA PVT LTD
REVENUE
BOLSTERING R&D
₹1739 crore
Hyderabad-based Sanofi Healthcare India, formerly known
DR KI as Shantha Biotechnics, generated a revenue worth Rs 1739
VARAPRASAD REDDY crore in the biopharma space during FY 20-21, exhibiting
a slight decline in business in comparison to the revenue
Director generation of Rs 1761 crore in the previous fiscal.
A pioneer in the field of biotechnology, Shantha Biotechnics was the
first Indian company to develop, manufacture and market a recombinant
human healthcare product in India.
The company is currently focusing its R&D efforts in the development
of generic biologicals, novel therapeutic antibodies, proteins and
vaccines. Shantha conducts exploratory research in the fields of oncology,
infectious diseases and platform technologies.
SHANVAC- B is the first Indian Hepatitis-B vaccine to be pre-qualified
by the World Health Organisation (WHO) for supplying to UN agencies
globally. Shantha caters to major international markets including
Asia-Pacific, Africa, CIS and Latin America in addition to UNICEF and
PAHO. The company has also obtained WHO pre-qualification for its
combination vaccine of DPT+ Hepatitis-B vaccine SHANTETRA, enabling
supplies to UN agencies.
The other vaccines developed by the company include ShanTT
against tetanus; ShanHib against infections caused by Hemophilus
influenzae type-B; Shan5 which is India’s first indigenously developed
liquid pentavalent vaccine (DTP-Hep B-Hib). Shan5 protects infants
from five major childhood diseases i.e., Diphtheria, Pertussis (Whooping
cough), Tetanus, Hepatitis-B, Infections from Hemophilus influenzae
type-B. Shanpoietin (recombinant human erythropoietin) is a
glycoprotein produced in mammalian cells by inserting the gene coding
for human erythropoietin. Erythropoietin is used in the treatment of
anemia.
Additionally, in an effort to enrich and prolong the life of cancer
patients through cost-effective therapies, Shantha has launched the
CYTOCREST initiative. Under this initiative, the company has introduced
several new generation oncocare products which are either being
developed in-house or through alliances with major pharmaceutical
companies. The whole gamut of therapies in cancer care have
been planned under the flagship of CYTOCREST which includes
chemotherapeutics, biological therapy and supportive therapy, for
marketing in India only.
The research efforts at Shantha are further strengthened by
collaborative arrangements and alliances with leading research
institutions in India and abroad. Shantha’s R&D centre is recognised by
the Department of Scientific and Industrial Research, Government of
India.
The company is equipped with a state-of-the-art R&D facility, ideally
designed for development of biologics, based on modern biotechnology.
The facility has 50,000 sq.ft of laboratory area, divided in four independent
laboratories.

28 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

04 NOVO NORDISK INDIA PVT LTD

REVENUE RAISING BAR OF INNOVATION

₹1467 crore The Indian arm of Denmark headquartered company Novo
Nordisk saw a revenue generation of Rs 1467 crore during FY
VIKRANT SHROTRIYA 20-21 in the biopharma space, maintaining a smooth sail in
comparison to the revenue generation of Rs 1465 crore in the
Managing Director previous year.
During FY 20-21, the growth in employees was mainly driven by
international operations, with the highest growth rate in China. Novo
Nordisk also continued to increase the number of employees in Global
Business Services (GBS) in India, which grew by 14 per cent compared
with last year.

Novo Nordisk insulins have been present in India from 1935 marking
more than 80 years of uninterrupted supply. The India arm started
operations in 1992 with its headquarters in Bengaluru. The company now
has over 1,300 employees, and is the 5th largest and one of the fastest
growing pharmaceutical MNCs in India.

Globally, 2020 was a breakthrough year for the company’s latest
GLP-1 products, with Ozempic, a once weekly injectable, now launched
in 52 countries around the world and Rybelsus, a semaglutide based oral
medicine, now launched in nine countries around the world.

Within diabetes, the company is further raising the innovation bar
with the roll-out of the world’s first once-daily GLP-1 tablet, Rybelsus,
while at the same time working on novel insulins, 100 years after
the discovery of the molecule. The Research & Development (R&D)
team is also pursuing greater weight loss in obesity, and in 2020 they
demonstrated the potential of semaglutide 2.4 mg in the STEP phase 3
clinical trial programme.

Together with Massachusetts Institute of Technology, the company
is continuing to progress the development of systems enabling the
oral delivery of macromolecules, including the tortoise shell-inspired,
self-orienting oral device ‘SOMA’, with the ultimate ambition of one day
delivering insulin in a tablet.

Commercially, 2020 was a challenging year as lockdowns reduced the
time doctors spent with their patients, leading to fewer initiations of new
treatments. Despite this, the company expanded its leadership position
in the diabetes market in terms of value, keeping it on track to reach a
share of more than one third by 2025. Diabetes sales were driven by sales
of GLP-1 products (Victoza, Ozempic and Rybelsus), which offset mixed
market conditions for insulins.

Novo Nordisk also broadened the technology platforms and
expanded research into adjacent disease areas in 2020 including
cardiovascular disease, non-alcoholic steatohepatitis (NASH) and
Alzheimer’s disease – areas of huge unmet medical need and a great
burden for patients, families and society alike.

The acquisition in 2020 of US-based biotech company Corvidia
Therapeutics further strengthened its pipeline by introducing the anti-
IL-6 monoclonal antibody, ziltivekimab, which has shown encouraging
results in phase 2 on inflammatory biomarkers in patients with
atherosclerotic cardiovascular disease and chronic kidney disease. During
2020, it also acquired Emisphere Technologies.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 29

05 BHARAT BIOTECH
INTERNATIONAL LTD
REVENUE
ACHIEVING GLOBAL SUCCESS
₹1439 crore
During FY 20-21, Hyderabad-based Bharat Biotech saw a
DR KRISHNA ELLA revenue generation of Rs 1439 crore within the biopharma
space, exhibiting a growth of 35 per cent when compared to
Chairman and Managing Director the revenue generation of Rs 1066 crore in FY 19-20.
At the onset of the pandemic in 2020, Bharat Biotech
undertook an international collaboration with virologists at the University
of Wisconsin (UW) Madison and the vaccine company FluGen to begin
the development and testing of a unique vaccine against COVID-19 called
CoroFlu. CoroFlu is being built on the backbone of FluGen’s flu vaccine
candidate known as M2SR. Based on an invention by UW–Madison
virologists and FluGen co-founders, M2SR is a self-limiting version of the
influenza virus that induces an immune response against the flu.
Soon after, Bharat Biotech started to lead the New Millennium
Indian Technology Leadership Initiative by the Council of Scientific and
Industrial Research (CSIR) to develop human monoclonal antibodies as
therapy for COVID-19 infections.
The company also announced a partnership with US-based Thomas
Jefferson University to develop a new vaccine candidate for COVID-19
invented at Jefferson. The novel vaccine is being developed using an
existing deactivated rabies vaccine as a vehicle for coronavirus proteins.
Around the same time, Bharat Biotech successfully developed
COVAXIN, India’s first vaccine candidate for COVID-19, in collaboration
with the Indian Council of Medical Research (ICMR) - National Institute
of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and
transferred to Bharat Biotech. The indigenous, inactivated vaccine was
developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level
3) High Containment facility located in Genome Valley, Hyderabad.
The vaccine is developed using Whole-Virion Inactivated Vero Cell
derived platform technology. With more than 200 million doses having
been administered to adults and children outside the US, COVAXIN is
currently authorised under emergency use in more than 20 countries,
and emergency use authorisation is in process in more than 60 other
countries.
The FY 20-21 saw Norway-based Coalition for Epidemic Preparedness
Innovations (CEPI) granting $14.1million to consortium of Bharat
Biotech and International Vaccine Institute to advance development of
Chikungunya vaccine in collaboration with the Indian government.
The company also announced a licensing agreement with
Washington University School of Medicine in St. Louis for a novel chimp-
adenovirus, single dose intranasal vaccine for COVID-19. Bharat Biotech
owns the rights to distribute the vaccine in all markets except USA, Japan
and Europe.
Further ahead in 2020, Ocugen, Inc. signed a binding letter of intent
(LOI) with the vaccine manufacturer to co-develop Bharat Biotech’s
COVID-19 vaccine, COVAXIN, for the United States market. The FY 20-21
also saw GlaxoSmithKline, PATH and Bharat Biotech signing a product
transfer agreement for the malaria vaccine, RTS,S/AS01E.

30 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

06 BIOLOGICAL E LTD

REVENUE PIVOTING ON AFFORDABILITY

₹1418 crore Hyderabad-based Biological E (BE) clocked in a revenue figure
of Rs 1418 crore during FY 20-21 in the biopharma space,
MAHIMA DATLA showing a growth of 36 per cent when compared to the
revenue generation of Rs 1040 crore during FY 19-20.
Managing Director In 2020, Biological E entered into an agreement with
Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical
companies of Johnson & Johnson, for the creation and enhancement
of manufacturing capacities for drug substance and drug product for
Johnson & Johnson’s COVID-19 vaccine candidate, Ad26.COV2.S.
The company later announced a licensing agreement with US-based
Baylor College of Medicine for the development of a safe, effective and
affordable COVID-19 vaccine.
BE licensed the recombinant protein COVID-19 vaccine candidate
developed at Baylor. The company engaged in license negotiations with
the BCM Ventures team, part of Baylor College of Medicine, after initial
discussions on Baylor’s technology and how it could possibly inform a
vaccine to address the current global pandemic. The company leveraged
its past experience for the further development and commercialisation of
the vaccine candidate, produced using a proven yeast-based expression
technology.
The vaccine Corbevax, developed by Texas Children’s Hospital Center
for Vaccine Development, includes an antigen in-licensed from BCM
Ventures, Baylor College of Medicine’s integrated commercialisation
team, along with Dynavax’s advanced adjuvant CpG 1018. Later in the
year, Norway-based Coalition for Epidemic Preparedness Innovations
(CEPI) announced a collaboration with BE to advance the development
and manufacture of Corbevax by contributing up to $5 million towards
the cost of scaling up the process for manufacturing the vaccine.
Corbevax is India’s first indigenously developed receptor-binding domain
protein subunit vaccine.
Simultaneously, Ohio State Innovation Foundation (OSIF) in the US
licensed novel live attenuated measles virus vectored vaccine candidates
against SARS-CoV-2, which were developed by the Ohio State University
College of Veterinary Medicine, exclusively to BE.
The FY 20-21 also saw BE acquiring Akorn India Limited, a subsidiary
of Akorn Inc., USA. With this strategic acquisition, BE intends to enhance
its manufacturing capabilities and capacities to produce and supply its
vaccines and injectable medicines. The Akorn India plant in Paonta Sahib,
Himachal Pradesh has a fully staffed sterile injectable manufacturing
facility with a 39,000 sq. mtrs of built up area spread over a 14-acre
campus with an annual capacity for about 135 million units with the
potential for immediate expansion of a further 30 million units.
In 2020, the company further announced that its Typhoid Conjugate
Vaccine (TCV) has been pre-qualified by the World Health Organisation
(WHO). With this pre-qualification, BE became one of two pre-qualified
suppliers of TCV to the UN agencies. BE’s TCV is a single-dose injectable
vaccine, which can be administered to children from 6 months of age
to adults up to the age of 45 and it is formulated with Vi polysaccharide
conjugated to a carrier protein.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 31

07 RELIANCE LIFE SCIENCES PVT LTD

REVENUE CONTINUOUSLY DEVELOPING

₹1418 crore Mumbai-based Reliance Life Sciences (RLS) generated
revenue worth Rs 1404 crore during FY 20-21 in the
KV SUBRAMANIAM biopharma space, exhibiting a growth of 38 per cent, in
comparison to the revenue generation of Rs 1018 crore in
President the previous fiscal.
During the year, despite the daunting challenges posed by COVID-19
pandemic, Reliance Life Sciences was able to build and scale up COVID-19
RT-PCR and antibody testing facilities. The company developed and
manufactured Molecular Transport Media (MTM) for safe transport of RT-
PCR samples and with scalability
It also introduced 8 new products – prothrombin complex
concentrate, ranibizumab, denosumab (oncology), sunitinib, sorafenib,
MTM, bacteriostatic water for injection (bWFI) and sterile water for
injection (sWFI); and obtained several product registrations overseas
FY 20-21 saw the company working tirelessly towards manufacturing
products used to treat COVID-19 patients in intensive and critical care
units in hospitals.
RLS, part of the Promoter Group of Reliance Industries Limited, ended
the financial year 2021-22 on an excellent note with strong revenue growth.
This high growth has been primarily driven by greater market participation,
entry into newer markets, scaling up of RT-PCR testing capacities and
expanding manufacturing capabilities. The company has forayed into
innovative technology domains and is building a new life sciences campus
at Nashik. RLS continued to grow despite the challenges posed by the
second and third waves of COVID-19, by balancing biosafety with progress.
RLS envisages the new financial year 2022-23 to be even better with
new avenues of growth and development, in terms of business domains,
new products and new manufacturing facilities.
2020 also saw the company entering the list of vaccine developers
for COVID-19. The vaccine is a protein subunit one, and is expected to be
safe for all age groups. It has a unique construct, which is expected to be
effective against a range of COVID-19 variants; going by data emanating
from extensive in-vitro and animal studies.
RLS has launched five of the world’s first biosimilars, has the largest
number of biosimilars in the market in India, and the highest number of
biosimilars under development globally. It has the distinction of being
the first integrated manufacturer of plasma proteins in South Asia. The
company has catalysed the emergence of regenerative medicine in
the country, and has the highest experience with cord blood stem cell
transplants in India. RLS is one of the few centres in the world offering a
specialised range of tests in molecular medicine and molecular genetics.
Consistent with the diversity and depth of its initiatives, the company
has a professional team of Ph.Ds, M.Ds, Engineers and Post Graduates in
Science. The average age of the Reliance Life Sciences team is 35 years
and 22 per cent of the employees are women. It operates state-of-the-art
facilities in the life sciences domain. The flagship facility is the Dhirubhai
Ambani Life Sciences Centre (DALC) in Navi Mumbai. Spread over 20
acres, DALC is among the most diverse and integrated life sciences
campuses in the world.

32 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

08 SANOFI INDIA LTD

REVENUE MAKING SIGNIFICANT INVESTMENTS

₹1101 crore The Indian arm of the French multinational pharmaceutical
company, Sanofi India generated a revenue figure of Rs 1101
RODOLFO HROSZ crore during FY 20-21 in the biopharma space, showing a slight
growth of 5 per cent in comparison to the revenue generation
Managing Director of Rs 1052 crore in FY 19-20.
Sanofi Pasteur India, the vaccines global business unit of Sanofi
announced the launch of Tetraxim (DTaP-IPV) in 2020. The booster
vaccine is indicated for preschoolers and provides protection against
four major diseases - Diphtheria, Pertussis, Tetanus and Polio. Tetraxim
combines four vaccines into one, thus reducing the number of injections,
increasing comfort and improving vaccination compliance for children
and reducing parental anxiety.

With Tetraxim, Sanofi Pasteur currently protects school children in
more than 100 countries, with 63 million doses distributed worldwide.
The Indian Academy of Pediatrics, an association of Indian paediatricians,
recommends full dose DTaP for preschoolers.

The FY 20-21 also witnessed Sanofi Pasteur India launch VaxLine,
a 24X7 helpline that provides online and offline support to empower
parents with detailed information on managing vaccination of their
babies and children during and post the COVID-19 pandemic. The
helpline addressed questions on interrupted vaccination and routine
immunisation including guidance on what parents can do till they restart
the vaccination schedule of their children.

During 2020, the company launched a multi-channel educational
initiative to raise awareness about allergies and their impact on the
quality of life. In India, prevalence of allergies has increased five times, but
50 per cent of the allergy sufferers are unaware of this problem. Sanofi
is also running educational programmes from time to time including
medical experts and people living with allergies to help understand
allergies better.

On the global front, Sanofi signed a renewed partnership agreement
with the World Health Organisation (WHO), consolidating a 20-year
collaboration to fight some of the most Neglected Tropical Diseases
(NTDs) and supporting the WHO in its commitment to sustainably
eliminate sleeping sickness before 2030.

The company also signed a letter of intent with GSK to develop an
adjuvanted vaccine for COVID-19, using innovative technology from
both companies, to help address the ongoing pandemic. While Sanofi
agreed to contribute its S-protein COVID-19 antigen, which is based on
recombinant DNA technology, GSK contributed its proven pandemic
adjuvant technology.

Adding on, Sanofi Pasteur and Translate Bio, a clinical-stage
messenger RNA (mRNA) therapeutics company, collaborated to develop
a novel mRNA vaccine for COVID-19. This collaboration leverages an
existing agreement from 2018 between the two companies to develop
mRNA vaccines for infectious diseases.

Sanofi also announced a collaboration with the Biomedical Advanced
Research and Development Authority (BARDA) to advance a novel
COVID-19 vaccine candidate.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 33

09 INTAS PHARMACEUTICALS LTD

REVENUE ACCELERATING INNOVATION

₹1071 crore For Ahmedabad-based Intas Pharmaceuticals, FY 20-21 saw a
revenue generation of Rs 1071 crore in the biopharma space,
BINISH CHUDGAR showing a growth of 26 per cent in comparison to the revenue
generation of Rs 850 crore during FY 19-20.
Managing Director In 2020, New Delhi-based Naari Pharma Private Limited
entered into a definitive asset purchase agreement to acquire 10
Abbreviated New Drug Applications (ANDAs) for the US market from
Intas Pharmaceuticals. The portfolio acquired comprises eight US FDA
approved ANDAs and two products pending approval. It includes generic
products in female hormones which will be manufactured at Naari’s
dedicated female hormone facility in India and commercialised in the
coming months.
During its fights against COVID-19, the R&D team at Intas Pharma
developed COVID-19 specific Hyperimmune Globulin as treatment for
patients suffering from moderate to severe infection. Hyperimmune
Globulin also has potential for use as prophylaxis for all high-risk
populations in contact with COVID-19 patients. This product was
developed as an important therapeutic option that can potentially help
combat the disease.
Intas received permission from the Drug Controller General of India
(DCGI), to conduct clinical trials by using the newly developed COVID-19
specific Hyperimmune Globulin. After establishing its usefulness in the
clinical trial, this product was made available for use in treating COVID-19
patients.
Intas was among the world’s first to adopt a new approach for
treating COVID-19 patients. This came across as a Corporate Social
Responsibility (CSR) initiative from Intas in collaboration with all Indian
Blood Banks that were helping to procure convalescent plasma (plasma
extracted from patients recovered from COVID-19 infection).
The company established an alliance with medical and research
institutions, blood donation groups to collect the plasma from recovered
COVID-19 patients. Intas also launched a website to help recovered
COVID-19 patients to locate the nearest blood bank where they could
safely donate plasma. The company took government support to
facilitate the supply of convalescent plasma for the manufacturing of
the enriched Hyperimmune Globulin and thereby help more patients
conquer COVID-19.
During FY 20-21, South Korean firm Alteogen Inc entered into an
exclusive license agreement with Intas to use ALT-B4, Alteogen’s novel
hyaluronidase, derived utilising the Hybrozyme technology, to develop
and commercialise two products.
Under the terms of the agreement, Alteogen granted worldwide
rights, except for a few Asian countries, for Intas to develop two products
in combination with ALT-B4. Alteogen will receive an initial payment of
$6 million and is also eligible to receive additional milestones upon Intas’
achievement of specified development, regulatory and sales milestones,
totalling up to $109 million.
Headed by a strong pool of 550+ scientists and researchers, till date
Intas has filed 50+ patents.

34 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

10 GLAXOSMITHKLINE
PHARMACEUTICALS LTD
REVENUE
GATHERING NEW PROSPECTS
₹966 crore
During FY 20-21, revenue generation for the Indian arm of UK-
SRIDHAR VENKATESH based GlaxoSmithKline (GSK) in the biopharma space stood
at Rs 966 crore, exhibiting a slight decline in comparison to
Managing Director the revenue generation of Rs 1065 in the previous year.
The company’s established portfolio made gains in
their market share in respective categories, particularly in the anti-
infectives and pain therapeutic areas which have been crucial in the fight
against COVID-19. GSK India also continued to maintain its leadership in
dermatology.
In April 2020 GSK announced a collaboration with Sanofi which
combines their S-protein COVID-19 antigen with GSK’s pandemic
adjuvant technology. Together with Sanofi, GSK secured supply
agreements with the US, UK, EU and Canada and a statement of intent
with COVAX, a global initiative that aims to ensure equitable international
distribution of effective COVID-19 vaccines, as part of the company’s
commitment to make this vaccine available globally. In December, GSK
announced a delay to the development programme and started a new
phase II study in February 2021.
In July, the company announced a collaboration with Medicago to
develop another COVID-19 candidate vaccine. Phase I clinical testing
began that month on a vaccine combining an innovative plant-based
antigen and GSK’s adjuvant. The trials moved into phase II/III clinical
development in November 2020. GSK announced another adjuvanted
COVID-19 vaccine collaboration in February 2021, with SK Bioscience,
which entered phase I testing. The collaboration to develop an
adjuvanted COVID-19 vaccine with China-based Clover Pharmaceuticals
was stopped in early 2021.
Also, in February 2021, GSK announced a new collaboration with
the German biotechnology company CureVac to jointly develop next
generation mRNA vaccines for COVID-19.
During FY 20-21, the company also announced a COVID-19
partnership, with clinical-stage immunology company Vir Biotechnology,
to identify and accelerate therapeutic and preventative antibody
therapies against the virus. Within six months of the agreement with Vir,
the VIR-7831 (GSK4182136) antibody, for the early treatment of COVID-19
patients at high risk of hospitalisation, moved to a global phase III trial.
In 2020, following a review of its marketed medicines and pipeline
products to identify agents that might be able to treat the COVID-19
virus or secondary complications, GSK started a phase II proof of concept
OSCAR study with otilimab for treating severe pulmonary COVID-19-
related disease. In February 2021, the company announced results from
the study, which showed the primary endpoint did not reach statistical
significance across all ages, but an efficacy analysis by age showed a
potentially important clinical benefit in patients 70 years and older. Based
on the public health need, GSK decided to expand the OSCAR study to
confirm these potentially important findings.
In early 2021, GSK, PATH and Bharat Biotech announced a product
transfer agreement for a malaria vaccine.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 35

11 Mumbai-based Bharat Serums and Vaccines (BSV) generated
revenue worth Rs 942 crore during FY 20-21 in the biopharma
BHARAT SERUMS space, exhibiting a slight growth of 3 per cent in comparison
AND VACCINES LTD to the revenue generation of Rs 917 crore in FY 19-20. The FY
20-21 saw the company conducting phase III clinical study
REVENUE of sepsis drug, Ulinastatin for treating acute respiratory distress syndrome
(ARDS) patients, in its fight against COVID-19. BSV also initiated a research
₹942 crore project to co-develop an equine polyclonal antibody against COVID-19.
Clinical safety of equine immunoglobulins through consistent quality
SANJIV NAVANGUL and safety of its equine products over the past two decades gave BSV the
confidence to take up this project. BSV is the first company in India to
Managing Director & get the Drugs Controller General of India (DCGI) approval for Liposomal
Chief Executive Officer Amphotericin B, the antifungal medication used in the treatment of this
condition and also marketing Liposomal Amphotericin B in India and
exporting it to many other countries.

12 Hyderabad-based vaccine manufacturer Indian Immunologicals (IIL)
recorded a revenue of Rs 747 crore in FY 20-21 in the biopharma
INDIAN space exhibiting a decline in business by 9 per cent from the
IMMUNOLOGICALS last fiscal’s revenue of Rs 820 crore. 2020 saw the vaccine maker
LTD joining hands with Griffith University of Australia by entering into
an agreement for research collaboration to develop a lead vaccine candidate
REVENUE for coronavirus. In this significant cross-continental collaboration, scientists
from Indian Immunologicals and Griffith University started working on a
₹747 crore ‘Live Attenuated SARS–CoV-2 vaccine’ using the latest codon de-optimisation
technology. This technology has been successfully employed to reduce the
DR K ANAND KUMAR virulence of several RNA viruses including Enterovirus C (Poliovirus), Human
Immunodeficiency virus type 1, Zika virus, etc. The company is already working
Managing Director with Griffith University for conducting research and development of Zika virus
vaccine which is currently at preclinical toxicology testing stage. The joint project
has been progressing well and Indian Immunologicals is expected to submit the
application for conducting clinical trials in due course.

13 Ahmedabad-based Zydus Lifesciences Ltd (Formerly Zydus Cadila)
recorded a revenue of Rs 646 crore during the FY 20-21 in the
ZYDUS biopharma space, as compared to Rs 513 crore earned in the FY
LIFESCIENCES 19-20, marking a significant growth of 26 per cent. The onset of the
LTD pandemic in 2020 led the company to explore the biologicals route
to treat novel coronavirus with long-acting Interferon alpha-2b. On the other
REVENUE hand, COVID-19 Kavach Elisa tests were manufactured by Zydus Diagnostics,
a unit of the company, and supplied to Indian Council of Medical Research
₹646 crore (ICMR), free of cost. Zydus also signed non-exclusive licensing agreement with
Gilead Sciences Inc., for the manufacturing and distribution of Remdesivir, the
PANKAJ R PATEL investigational drug, which had been issued an Emergency Use Authorisation
by the US Food and Drug Administration (FDA) to treat patients suffering from
Chairman severe symptoms of COVID-19. During FY 20-21, the company also undertook
trials of Desidustat, an oral small molecule hypoxia-inducible factor prolyl
hydroxylase (HIF-PH) inhibitor for treatment of anaemia in patients with
Chronic Kidney Disease (CKD). Another major headway during FY 20-21 was the
development of a plasmid DNA vaccine against COVID-19.

36 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

14 During FY 20-21, Ahmedabad-based Concord Biotech clocked in a
revenue figure of Rs 616 crore in the biopharma space, exhibiting a
CONCORD growth of 13 per cent, when compared to the revenue generation of
BIOTECH LTD Rs 543 crore in the previous year. A majority of this revenue came in
from exports. With an R&D expenditure of Rs 19 crore, the company
REVENUE launched 3 new products in FY 20-21. With the commissioning of the new
fermentation facility, launch of several biotech Active Pharmaceutical Ingredients
₹616 crore (APIs) in the pipeline and new collaborations with global biopharmaceutical
companies on contract research and manufacturing projects, Concord expects
ANKUR VAID a robust growth in the coming year. The company has a workforce of 1009
employees with 92 in R&D, 302 in manufacturing, 153 in sales, 175 in support
Chief Executive Officer & and 287 in operations. Concord intends to increase the capacity of its existing
Joint Managing Director products and also commercialise new fermentation APIs to meet customer
demands and cater to Indian and global markets. The company is globally known
15 for its products and has a commanding presence in more than 50 countries
worldwide.
PFIZER LTD
The Indian business of American multinational pharmaceutical
REVENUE corporation Pfizer recorded a revenue generation of Rs 538 crore in
the biopharma space during FY 20-21, showing a slight growth when
₹538 crore compared to the revenue figures of FY 19-20 which stood at Rs 519 crore.
Headquartered in Mumbai, Pfizer India got started in 1950. In India,
S SRIDHAR when the COVID-19 pandemic continued to spread rapidly during 2020-2021, the
company’s sales, primarily for hospitals and vaccines businesses, were impacted.
Managing Director Besides, the company completed the wind down activities for its consumer
healthcare business consisting of two brands Anacin and Anne French. On the
global front, Pfizer and BioNTech announced plans in April 2020 to jointly develop
COVID-19 vaccine, initially in the US and Europe, and scale-up manufacturing
capacity to support global supply. The Pfizer-BioNTech COVID-19 Vaccine, which
is based on BioNTech’s proprietary mRNA technology, is developed by both
BioNTech and Pfizer. BioNTech is the current Marketing Authorisation Holder in
the US, the EU, the UK, Canada and the holder of emergency use authorisations or
equivalents in the United States (jointly with Pfizer) and other countries.

16 Mumbai-based Macleods Pharmaceuticals recorded a revenue of
Rs 488 crore during FY 20-21 in the biopharma space, showing
MACLEODS a slight growth of 4 per cent from the previous financial year
PHARMACEUTICALS where the revenue count was Rs 471 crore. With an experience
PVT LTD of more than 2 decades, Macleods is an established name in the
Indian pharmaceutical market. With its diversified product portfolio, Macleods
REVENUE has gained leadership in various therapeutic segments. The company’s product
portfolio encompasses a wide spectrum of therapeutic groups, ranging from
₹488 crore anti-TB, asthma & COPD, anti-bacterial, NSAID, anti-arthritic, anti-osteoporotic,
gastroenterology, gynaecology, diabetology and CVS products. The R&D centre at
RAJENDRA AGARWAL Macleods is located in Mumbai, which was setup in the year 2000, and is approved
by the Department of Scientific and Industrial Research, Government of India.
Managing Director Besides that, the company also has a bioequivalence department established in
2005. Its clinical and bio-analytical facilities and processes are inspected by the
Drugs Controller General of India (DCGI), US FDA, WHO and MCC (South Africa).
In addition, the manufacturing facilities at Macleods are approved by regulatory
agencies including USFDA, MHRA, WHO, to name a few.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 37

17 For FY 20-21, Mumbai based Lupin recorded a revenue generation of
Rs 442 crore in the biopharma space as compared to Rs 424 crore
LUPIN LTD generated in the previous financial year, exhibiting a growth of 4 per
cent. During 2020, Lupin announced a long-term strategic alliance with
REVENUE Omron Healthcare India to strengthen respiratory disease management
facilities in India mainly focusing on asthma and chronic obstructive pulmonary
₹442 crore disease (COPD) patients. The company also launched Favipiravir in India under
the brand name Covihalt for the treatment of mild to moderate COVID-19.
VINITA D GUPTA Favipiravir received authorisation from the Drug Controller General of India
(DCGI) for emergency use. A few other developments by Lupin in FY 20-21 include
Chief Executive Officer the launch of Nepexto, biosimilar etanercept, in the German market; agreement
with US-based PlushCare to allow treatment for bacterial vaginosis (BV) in
adult women, via the PlushCare virtual platform; and entering into distribution
agreement with three companies for its orphan drug NaMuscla (mexiletine) for
the symptomatic treatment of myotonia in adults with non-dystrophic myotonic
(NDM) disorders in certain EU territories.

18 Arevenue generation of Rs 406 crore has been recorded for the Indian
arm of the American healthcare company Abbott Laboratories in
ABBOTT the biopharma space for FY 20-21. This marks a 3 per cent growth
INDIA LTD for the company in comparison to the revenue generation a year
before which was summed up at Rs 395 crore. The vaccines portfolio
REVENUE of the company showed strong double digit growth of 42.3 per cent, which
was mainly driven by Influvac (for prevention of influenza). Influvac is the key
₹406 crore brand for the company under this portfolio and leads its participating market.
Abbott has a licensing arrangement with Bharat Biotech to market vaccines
ANIL JOSEPH in the immunology segment. The key brands under this arrangement are
Enteroshield (for prevention of typhoid) and Rotasure (for prevention of rotavirus
Managing Director gastroenteritis). The launch of a very critical adult immunisation guideline
for vaccine-preventable diseases by the Association of Physicians in India
(API) by the company has been carried out to increase awareness and equip
healthcare practitioners (HCP) with evidence-based information to guide vaccine
recommendation and administration.

19 Pune-based Venkateshwara Hatcheries generated revenue worth Rs
308 crore in the biopharma space during FY 20-21, exhibiting a slight
VENKATESHWARA growth in comparison to the revenue generation of Rs 299 crore
HATCHERIES in previous year. As the first company to embark on a process of
PVT LTD developing the industry on scientific lines, Venkateshwara Hatcheries
occupies a special place in the Indian poultry scene. It pioneered the concept
REVENUE of parent franchisee operations, popularised cage farming, and introduced for
the first time in India, the concept of inactivated vaccines and combination
₹308 crore vaccines, and more importantly, use of SPF eggs in vaccine production. Its parent
company, VH Group is popularly known the world over as Venky’s. It is the largest
DR ANURADHA J. DESAI, fully integrated poultry group in Asia. Within the vaccine business, the company
has developed a range of poultry vaccines in the live and inactivated categories.
Chairperson, VH Group These vaccines have been developed for the prevention of diseases such as
Marek’s, Newcastle, Avian infectious bronchitis, infectious bursal, inclusion body
hepatitis, Avian reovirus, Chicken infectious anaemia, to name a few.

38 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

20 During FY 20-21, Mumbai-based Wockhardt clocked in revenue worth
Rs 231 crore in the biopharma space, showing a growth of 10 per
WOCKHARDT cent when compared to the revenue figure of Rs 210 generated
LTD during FY 19-20. FY 20-21 saw the company entering into an
agreement with the UK Government to fill-finish COVID-19 vaccines.
REVENUE The manufacturing was undertaken at CP Pharmaceuticals, a subsidiary of
Wockhardt based in Wrexham, North Wales. As per the terms of the agreement,
₹231 crore the company reserved manufacturing capacity to allow for the supply of multiple
vaccines to the UK Government in its fight against COVID-19, including AZD1222,
DR HABIL KHORAKIWALA the vaccine co-invented by the University of Oxford and its spinout company,
Vaccitech and licensed by AstraZeneca. After a few months, the company was
Founder Chairman awarded a six-month extension of its agreement with the UK Government to
fill-finish COVID-19 vaccines. This expanded the original agreement from 18 to 24
months i.e., until August 2022. In addition, 5 patents were filed during the quarter
ended March 31, 2021 and the cumulative filings till date are 3187. The company
was granted 11 patents during the fourth quarter and now holds 763 patents.

21 New Delhi-based Panacea Biotec generated a revenue of Rs 228
crore in the biopharma space in FY 20-21 marking a growth of 62
PANACEA per cent when compared to the revenue generated during FY 19-20
BIOTEC LTD which was recorded at Rs 140 crore. In 2020, Panacea advanced its
response to address the unprecedented challenges of COVID-19 by
REVENUE collaborating with Refana Inc. USA to make COVID-19 vaccine widely accessible
around the world in an equitable manner through a joint venture company based
₹228 crore in Ireland. The company also announced successful completion of its Phase I/II
study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-
DR RAJESH JAIN dose live-attenuated tetravalent vaccine. Panacea through continued support
from National Institutes of Health, Technology Development Board, and other
Managing Director stakeholders is in a better position to increase affordable access to DengiAll to
fight dengue, a disease that has eluded mankind for generations. Later towards
the end of FY 20-21, the Russian Direct Investment Fund (RDIF, Russia’s sovereign
wealth fund), and Panacea announced a cooperation to produce 100 million doses
per year of the COVID-19 vaccine candidate Sputnik V.

22 For FY 20-21, Mumbai-based Sun Pharma earned a revenue of Rs 213
crore in the biopharma space as compared to Rs 193 crore generated
SUN PHARMA in the previous financial year, exhibiting a profit of 10 per cent. The
INDUSTRIES LTD company, in 2020 received approval from the Drugs Controller General
of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate
REVENUE in COVID-19 patients. Nafamostat is approved in Japan for improvement of
acute symptoms of pancreatitis and treatment of Disseminated Intravascular
₹213 crore Coagulation (DIC). Simultaneously, Sun Pharma commenced Phase II clinical
trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of
DILIP SHANGHVI COVID-19. During FY 20-21, the company also launched FluGuard (Favipiravir
200 mg) at an economical price of Rs 35 per tablet, for the treatment of mild to
Managing Director moderate cases of COVID-19 in India. Alongside, Sun Pharma initiated Phase 2
clinical trial for SCD-044 (a novel, orally bioavailable sphingosine-1-phosphate
(S1P) receptor 1 agonist) in patients with moderate to severe plaque psoriasis.
The company also provided updates on its New Chemical Entity (NCE), GL0034
- a long-acting GLP-1R (Glucagon-Like Peptide-1 Receptor) agonist to treat
patients with type 2 diabetes.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 39

FRESENIUS KABI 23 ELI LILLY & COMPANY 24
INDIA PVT LTD INDIA PVT LTD

Pune-based Fresenius Kabi India, a 100 per Gurugram headquartered Eli Lilly and Company
cent subsidiary of Fresenius Kabi AG Germany, (India), a wholly owned subsidiary of US-based
recorded a revenue of Rs 205 crore in the biopharmaceutical firm Eli Lilly and Company
biopharma space during FY 20-21, exhibiting a recorded a revenue of Rs 172 crore in the biopharma
growth of 12 per cent when compared to the space during FY 20-21, showing a slight decline when
revenue generation in FY 19-20 recorded at Rs 182 compared to Rs 183 crore generated during FY 19-20.
crore. Established in 1995, Fresenius Kabi India Since its inception in India in 1993, the company has been
deals in clinical nutrition; IV drugs which formulate committed to developing and marketing pharmaceutical
intravenously administered generic drugs such as products to treat diabetes, gastric cancer, lung cancer,
oncology drugs, anesthetics & analgesics, anti-infective osteoporosis, rheumatoid arthritis, men’s health and
& critical care drugs. The portfolio also includes infusion growth-hormone deficiency. Lilly India affiliate comprises
therapy. operations in Nepal, Bangladesh and Sri Lanka.

HESTER 25 ABBOTT HEALTHCARE 26
BIOSCIENCES LTD PVT LTD

For FY 20-21, Ahmedabad-based Hester Biosciences Mumbai-based Abbott Healthcare witnessed
witnessed a revenue generation of Rs 162 crore a revenue generation of Rs 145 crore in the
in the biopharma space, exhibiting a growth of biopharma space during FY 20-21, marking
5 per cent in comparison to the revenue generated in a decline of 8 per cent in the business as compared
the previous year at Rs 154 crore. In 2020, the Indian to the last year’s revenue recorded at Rs 157 crore.
Institute of Technology, Guwahati (IIT-G) collaborated Founded in 1997, the company offers products in
with Hester Biosciences to work on the vaccine therapy areas such as respiratory, gastro, dermal,
development against COVID-19, based on recombinant nutritional, parenteral, anti-parasitic, gynecology,
avian paramyxovirus-based vector platform. It signed an ophthalmology and otolaryngology, oncology, cardiac,
agreement towards receiving the developed technology diabetes and hormones.
from the ICAR – IVRI, for developing the Brucella
Abortus S19 Delta Per vaccine for cattle.

MSD 27 LA RENON 28
PHARMACEUTICALS PVT LTD HEALTHCARE PVT LTD

Mumbai-based MSD Pharmaceuticals recorded a Ahmedabad-based La Renon Healthcare
revenue figure of Rs 99 crore in the biopharma recorded a revenue figure of Rs 90 crore during
space during FY 20-21, exhibiting a growth of FY 20-21 in the biopharma space, exhibiting
17 per cent when compared to its performance last a slight decline when compared to Rs 92 crore
year at Rs 85 crore. Through its prescription medicines, generated during previous financial year. The company
vaccines, biologic therapies, and animal health majorly caters to segments such as nephrology, critical
products, MSD operates in more than 140 countries. care, neurological disorders, urology, gastroenterology,
Since its existence in India, the company has moved respiratory and cardio metabolic. The company’s
quickly in laying the foundation for a business that is R&D centre has been accorded recognition by the
differentiated by its focus through launching innovative Department of Scientific and Industrial Research
products relevant to India. MSD in India also has a (DSIR), a department of the Ministry of Science and
presence in animal health via MSD Animal Health with Technology under the Government of India.
its vaccines facility located in Pune.

40 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

BHARAT IMMUNOLOGICALS 29 HAFFKINE BIO- 30
AND BIOLOGICALS PHARMACEUTICAL
CORPORATION LTD CORPORATION LTD

For FY 20-21, Bulandshahar-based Bharat The revenue generation for Mumbai-based
Immunologicals and Biologicals Corporation (BIBC) Haffkine Bio-Pharmaceutical Corporation, owned
witnessed a revenue generation of Rs 87 crore in the by the Maharashtra government, was recorded
biopharma space, thereby exhibiting a growth of 28 per at Rs 84 crore in the biopharma space during FY 20-
cent in comparison to the revenue generation of Rs 68 21, showing a dip of 33 per cent in comparison to the
crore in FY 19-20. The company currently manufactures revenue figure in FY 19-20 at Rs 126 crore. Haffkine
and produces a range of pharmaceutical products such as Ajintha Pharmaceuticals Ltd., a subsidiary of Haffkine
Oral Polio Vaccines (OPV Vaccine), Zinc Tablet & Diarrhea Bio-Pharma, develops a wide range of bacterial and
Management Kit etc. BIBC was established as a Public viral vaccines, formulates pharmaceutical products,
Sector Unit in 1989. Currently, the company is supporting disinfectants, ointments, injectables, syrups and
the COVID-19 vaccine manufacturing for Covaxin by mixtures. Haffkine introduced Scorpion Venom
Bharat Biotech, under Mission Covid Suraksha. Antiserum for the first time in India.

GLOBION INDIA 31 INDOVAX 31
PRIVATE LIMITED PVT LTD

Coimbatore-based Globion India, an arm of Suguna Gurugram-based poultry biotechnology company
Holdings Private Limited (SHPL), generated a Indovax recorded a revenue generation of Rs 80
revenue figure of Rs 80 crore during the FY 20-21 crore in the biopharma space during FY 20-21,
in the biopharma space, exhibiting a slight growth of 3 exhibiting a growth of 7 per cent as compared to the
per cent in comparison to the revenue generation of Rs revenue generation of Rs 74 crore during FY 19-20. The
78 crore in the previous fiscal. Globion produces a basket company’s product portfolio contains 12 live vaccines
of poultry vaccines, live and inactivated, for breeders, and 11 inactivated poultry vaccines. Incorporated in 1986,
layers and broilers. The products are marketed under the company produces over four billion doses of poultry
the brand GlobiVac. The year 2020 was an important vaccine annually that cater to the needs of the domestic
year for Globion wherein major decisions were taken in and international markets. This effort is supported
reorganising business priorities apart from optimisation by a team of qualified scientists drawn from diverse
of resources to become self-reliant and robust. disciplines.

BIOVET 32 DR. REDDY’S 33
PVT LTD LABORATORIES LTD

For Bengaluru-based Biovet, FY 20-21 saw a Hyderabad-based pharmaceutical company Dr.
revenue generation of Rs 75 crore leading to a dip Reddy’s Laboratories earned a revenue of Rs 71
of 32 per cent in its business, when compared to crore during FY 20-21 in the biopharma space,
the revenue generation of Rs 111 crore in the previous showing a decline of 10 per cent in its growth when
year. Biovet is an animal health vaccine producing compared to Rs 79 crore earned in FY 19-20. The year
company located at Malur, Karnataka. It currently 2020 saw Dr. Reddy’s acquiring select anti-allergy
has a world class Foot and Mouth Disease vaccine brands from Glenmark Pharma. The company also
production facility at the Malur KIADS near Bengaluru announced its partnership with Biotechnology Industry
and is committed to produce animal health care Research Assistance Council (BIRAC) for advisory
products including veterinary biologicals, bio-vaccines support on clinical trials of Sputnik V vaccine in India.
and other related products for large animals, poultry In addition, the company launched Remdesivir, under
and pet animals. a brand name Redyx, and Avigan (Favipiravir) 200 mg
tablets in India for COVID-19 treatment.

PROCESS DEVELOPMENT
TFF SYSTEMS

Cogent® Lab systems

One family of TFF systems with seamless scale-up or scale-down
Flexibly operates in UF/DF, microfiltration or SPTFF mode and across a wide range of parameters
User-friendly Bio4C® Control Software – with recipe steps, real-time data and reliable results
Ideally paired with Pellicon® cassettes and capsules

Overlapping flow range for seamless linear scalability

Systems

Flow range Cogent® Lab 150 Cogent® Lab 800 Cogent® Lab 6000
• 20–150 mL/min • 100–800 mL/min • 400–6 000 mL/min
• 50–264 cm² • 0.0176–0.22 m² • 0.1–1.14 m²

For additional information
please contact [email protected]

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck, the
vibrant M, Millipore, Millipak, Mobius and Emprove are trademarks of Merck KGaA, Darmstadt, Germany
or its affiliates. All other trademarks are the property of their respective owners. Detailed information
on trademarks is available via publicly accessible resources.

42 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

RANBAXY 34 BRILLIANT 35
LABORATORIES LTD BIO PHARMA PVT LTD

Gurugram-based Ranbaxy Laboratories The revenue generation for Hyderabad-based
generated a revenue of Rs 68 crore in the Brilliant Bio Pharma (BBP) was Rs 67 crore in the
biopharma space during FY 20-21 exhibiting a biopharma during FY 20-21. The business faced
growth of 20 per cent in comparison to the revenue a huge decline of 60 per cent in comparison to the
generation of Rs 57 crore in the previous fiscal. revenue generation of Rs 166 crore during the previous
Incorporated in India in 1961, Ranbaxy Laboratories fiscal. BBP has its presence in veterinary biologicals
is an integrated, research based, international comprising of viral vaccines against FMD and rabies,
pharmaceutical company, producing a wide range bacterial vaccines against Haemorrhagic Septicaemia,
of quality, affordable generic medicines, trusted Blackquarter and Enterotoxaemia, and Animal Health
by healthcare professionals and patients across Products including Antibiotics and Antibacterials,
geographies. Mumbai-based Sun Pharma completed Analgesics and Antipyretics, Dewormers, Ecto and Endo
the acquisition of Ranbaxy Laboratories in 2015. Parasiticides, Feed Supplements, Galactogogues etc.

MANKIND 36 MICRO 37
PHARMACEUTICALS LTD LABS LTD

The revenue generation for New Delhi-based For FY 20-21, Bengaluru-based Micro Labs
Mankind Pharmaceuticals was recorded at Rs 60 generated a revenue of Rs 58 crore in the
crore in the biopharma space during FY 20-21, biopharma space, showing a slight decline in its
showing a slight growth of 3 per cent in comparison business when compared to Rs 60 crore generated
to the revenue figure in FY 19-20 which stood at Rs in FY 19-20. Micro Lab’s product portfolio includes
58 crore. The year 2020 saw the company entering some of the topmost brands in various specialties like
into collaboration with South Korea-based Daewoong cardiology, diabetology, anti-infectives, ophthalmology,
Pharmaceutical for conducting Phase I clinical trial of a pain, etc. Established in 1973, Micro Labs is a multi-
long-acting intramuscular formulation of Niclosamide faceted healthcare organization with a proficient
against COVID-19. Mankind has over 1000 products marketing team, state-of-the-art manufacturing
being marketed and more than 200 products under facilities and R&D centres that are at par with
development. international standards.

PAVIOUR 38 RPG 39
PHARMACEUTICALS PVT LTD LIFE SCIENCES LTD

During FY 20-21, New Delhi-based Paviour Mumbai-based RPG Life Sciences recorded
Pharmaceuticals witnessed a revenue a revenue generation of Rs 50 crore in the
generation of Rs 51 crore in the biopharma biopharma space during FY 20-21, showing
space, showing a growth of 17 per cent in comparison a huge growth of 70 per cent when compared to
to the revenue generated during FY 19-20 at Rs 44 the revenue generated during FY 19-20 which stood
crore. The company was incorporated in 1998 with the at Rs 30 crore. With manufacturing facilities located
objective of importing, marketing and distribution of in Ankleshwar and Navi Mumbai, the company is
various pharmaceutical specialty products which are primarily focused on pharmaceuticals, fermentation
not indigenously produced. The company has entered and biotechnology. RPG Life Sciences, a part of
into marketing agreements with Biotest Pharma- RPG Enterprises, is operating in the domestic and
Germany, for marketing their pharmaceuticals in India international markets in the branded formulations,
and Nepal, and with Chiesi Farmaceutici SpA, Italy for global generics and synthetic APIs space.
marketing products in India and Bangladesh.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com PARTNER CONTENT 43

UPES-Merck Collaboration: A significant
step in skilling young researchers

I PROF. NEERAJ MAHINDROO

UPES is a research-centric university with a system, agarose gel electrophoresis, polymerase chain
multidisciplinary approach to providing quality reaction, centrifugation apparatus, Multiplex ELISA,
education, skill development and employability. SMCxPRO Immunoassay System, SNAP id® 2.0
The university has seasoned researchers in its teaching Protein Detection System, etc. Students in the workshop
faculty and industry specialists on the advisory boards. are encouraged to work independently.
UPES aims at improving the quality of human life by
providing solutions to long-standing research problems. Based on students’ feedback after attending the
Towards this goal, the university has developed relevant workshop, it is inferred that the program is being
research facilities and collaborations. Recently, UPES delivered in an informative and interactive way. Fun-
signed an MoU with Merck Life Sciences, which is one based activities, along with quizzes, are helping them in
of the leading biotech and pharmaceutical companies learning and building advanced skills. Each experiment
in the world that provides solutions to treat various is performed individually and repeated until they gain
lethal diseases. The alliance between UPES and Merck confidence in doing it by themselves. These skills are
has increased the learning potential of the students helping them in their research and jobs in industries.
manifold, leading to the modernization of academics and
skill enhancement, which paves a pathway towards a As an extension of this industry-academia
highly employable workforce for the industry. Combining collaboration, both these partners are planning to submit
the strength of two leading forces in technology and joint research collaborations, organise joint conferences,
academics, the UPES-Merck collaboration will enable and explore possibilities of internship programs.
students to have better problem-solving skills and Besides, they are also working to enable the exchange
knowledge of cutting-edge technologies. It will also of academic information and materials to support mutual
facilitate tech and knowledge transfer across the growth. The partnership will create more tech-driven
university and the industry. research in the area of health sciences, which will
enable students to acquire industry-ready skills.
As a result of this collaboration, students of
Bachelor’s, Master’s, and Ph.D. programs from the (The author is Professor & Dean at
School of Health Sciences and Technology, UPES, are UPES School of Health Sciences and Technology)
being trained at the Merck High-End Skill Development
Centre at IMTech, Chandigarh. The workshop
comprises several techniques in molecular biology.
It is being carried out through a series of lectures
followed by hands-on training sessions. Throughout the
sessions, students are exposed to the fundamentals of
recombinant DNA technology along with the ability to
handle instruments like nanodrop, gel documentation

44 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

ZOETIS 39 ZUVENTAS 39
INDIA LIMITED HEALTHCARE LTD

The Indian arm of the US- based Zoetis clocked in Mumbai-based Zuventas Healthcare witnessed a
a revenue figure of Rs 50 crore during FY 20-21 in revenue generation of Rs 50 crore for FY 20-21
the biopharma space, exhibiting a growth of 11 per in the biopharma space, exhibiting a decline in
cent when compared to the revenue generation of Rs 45 business by 12 per cent when compared to the revenue
crore in FY 19-20. Zoetis discovers, develops, manufactures figure recorded during FY 19-20 at Rs 56 crore. During FY
and commercializes medicines, vaccines and diagnostic 20-21, Zuventus received the nod from the government
products, which are complemented by biodevices, to conduct Phase 3 clinical trials of Aviptadil injectable
genetic tests and precision livestock farming. Zoetis formulation for COVID-19 treatment. A part of Emcure
serves veterinarians, livestock producers and people who Pharmaceuticals, Zuventas has its presence in the
raise and care for farm and companion animals in more biotechnology (Enoxarin, Eporise, Peglast) and vaccines
than 100 countries. (Vac T, Zuvirab & Zuvicella) segment. With more than 100
products in its kitty, It has 3 manufacturing facilities.

SAMARTH 40 CIPLA 40
LIFE SCIENCES PVT LTD LTD

For FY 20-21, Mumbai-based Samarth Life Sciences During FY 20-21, Mumbai-based pharmaceutical
recorded a revenue generation of Rs 44 crore in company Cipla generated a revenue figure of
the biopharma space, maintaining a steady flow Rs 44 crore in the biopharma space, exhibiting
in business when compared to the revenue generated a decline in business by 12 per cent in comparison to
during FY 19-20 at Rs 43 crore. Since its inception in the revenue generation of Rs 49 crore in the previous
1963, the company has built a product portfolio focused year. In 2020, the company announced a collaboration
on therapeutics areas such as cardiology, oncology, with Roche Products (India) Pvt Ltd to provide better
neurology, pulmonology, antenatal medicines, IVF access to innovative medicines for patients in India.
medicines, to name a few. The company researches, The company tied up with Gilead to launch remdesivir
develops, manufactures and markets a broad range of under its brand name CIPREMI to fight COVID-19. The
life saving critical drugs. company was also actively involved in commercialising
diagnostic tools for COVID-19 detection.

CADILA 41 ALNICHE 42
PHARMACEUTICALS LTD LIFE SCIENCES PVT LTD

Ahmedabad-based Cadila Pharmaceuticals New Delhi-based Alniche Life Sciences generated
generated a revenue of Rs 41 crore during FY 20-21 a revenue figure of Rs 38 crore in the biopharma
in the biopharma space, exhibiting a humongous space during FY 20-21, maintaining a steady
growth of 136 per cent as compared to Rs 17 crore worth phase in comparison to the revenue generation of Rs
revenue generated in FY 19-20. The company announced 37 crore in the previous year. A key development for
the launch of NuPTH, an osteoporosis biosimilar of Alniche during FY 20-21 was when it ventured into
Forteo in India, for the treatment of osteoporosis and manufacturing in its state-of-the-art facility under the
in patients with increased risk of fracture. Cadila also name of EffiKasia Lifesciences at Kangra, Himachal
launched biosimilar Rituximab for the Indian market in Pradesh. EffiKasia Lifesciences will manufacture
2020, used for treatment of blood cancer and rheumatoid pharmaceuticals, nutraceuticals and dermatologicals.
arthritis. It was launched under the brand name Ritucad. In the future, the company plans to expand its
Adalimumab biosimilar under the brand name Cadalimab manufacturing capacities to contract-manufacturing
for arthritis was also launched during FY 20-21. for others, thus making its mark in the CMO space.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 45

WALLACE 43 BOEHRINGER 44
PHARMACEUTICALS PVT LTD INGELHEIM INDIA PVT LTD

Goa-based Wallace Pharmaceuticals generated The Indian arm of Germany-based Boehringer
a revenue of Rs 31 crore in the biopharma space Ingelheim recorded a revenue generation of Rs 30
during FY 20-21, exhibiting a slight growth of crore in the biopharma space in FY 20-21, showing
8 per cent as compared to Rs 29 crore worth revenue a growth of 30 per cent when compared to the revenue
generated in FY 19-20. The company markets a basket generated during FY 19-20 at Rs 23 crore. The year 2020
of over 200 products focusing on antibiotics, gastro- saw Mumbai-based Boehringer Ingelheim India receiving
intestinal, rheumatology, dermatology, gynecology, government’s approval of Nintedanib for the treatment
diabetology, ENT and pediatrics. Wallace Pharma is a part of systemic sclerosis-associated interstitial lung disease in
of the Wallace Group which also handles Indi Pharma adults. The company also announced its partnership with
and Goodwin Biotechnology Inc. The Wallace Group is Cipla to co-market three new oral anti-diabetics drugs
primarily engaged in the manufacture and marketing of Oboravo (Empagliflozin), Oboravo Met and Tiptengio
formulation products in India as well as abroad. (Empagliflozin+Linagliptin) in India.

GREENSIGNAL 45 ALKEM 46
BIO PHARMA PVT LTD LABORATORIES LTD

Chennai-based GreenSignal Bio Pharma generated Mumbai-based Alkem Laboratories generated a
revenue worth Rs 28 crore during FY 20-21 in the revenue of Rs 26 crore in the biopharma space
biopharma space, thereby showing 2x growth in during FY 20-21, maintaining a steady balance in
business when compared to the revenue generation of Rs comparison to the revenue generation of Rs 25 crore in
13 crore in the previous year. GreenSignal is one of India’s the previous year. Owing to the pandemic, FY 20-21 saw
premier vaccine manufacturing companies with its Alkem launching Favipiravir in India under the brand
BCG vaccine being given to millions of children globally. name Alfluenza for the treatment of mild to moderate
Its BCG vaccine is freeze-dried live attenuated Bacillus COVID-19. Later in the year, the company also launched
Calmette - Guerin derived from strain of Mycobacterium Brivaracetam under the brand name Brivasure as an
for the prevention of tuberculosis. Another product in its affordable anti-epileptic drug for the treatment of
portfolio is BCG ONCO for Immunotherapy which is a live, epilepsy in India. Alkem joined hands with Tata Memorial
attenuated freeze-dried preparation. Centre to establish an advanced radiotherapy facility.

JUGGAT 47 ASTRAZENECA 48
PHARMA LTD PHARMA INDIA LIMITED

During FY 20-21, Mysuru-based Juggat Pharma For the Indian arm of the British pharmaceutical firm
generated a revenue count of Rs 25 crore AstraZeneca, the revenue generation was Rs 24 crore
in the biopharma space, growing slightly in during FY 20-21 in the biopharma space, showing
comparison to the revenue generated in FY 19-20 a growth of 12 per cent in comparison to the revenue
at Rs 24 crore. A part of Jagdale Industries, Juggat generation of Rs 21 crore in the previous year. During FY
Pharma manufactures tablets, liquid orals, capsules, 20-21, the company received marketing authorisation
granules and small volume parenterals. With from the government for Dapagliflozin (Forxiga) for the
around 40 products in its portfolio, the company treatment of patients with heart failure with reduced
has a distribution network that spans all over India. ejection fraction; Benralizumab (Fasenra) for asthma
In 2020, the company had announced its plans to patients; and anti-diabetic drug dapagliflozin for the
set up 2 plants in FY 21-22 to boost nutraceutical treatment of patients of chronic kidney disease (CKD) up
production. to stage III. On the global front, AstraZeneca was majorly
involved in COVID-19 vaccine development.

46 BIOPHARMA COMPANIES RANKING BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

JAGSONPAL 49 OZONE 50
PHARMACEUTICALS LTD PHARMACEUTICALS LTD

New Delhi-based Jagsonpal Pharmaceuticals New Delhi-based Ozone Pharmaceuticals
recorded a revenue generation of Rs 21 crore in recorded a revenue generation of Rs 20 crore
the biopharma space during FY 20-21, showing in the biopharma space in FY 20-21, showing a
a growth of 8 per cent when compared to the revenue decline in growth by 24 per cent when compared to
generated during FY 19-20 at Rs 19 crore. Founded the revenue generation of Rs 27 crore during FY 19-20.
in 1964, the company specialises in developing and Ozone Pharmaceuticals is a formulation based drug
manufacturing bulk drugs and pharmaceutical manufacturing and marketing company, with a focus
formulations. Besides India, It’s operations span Russia, across 14 therapy areas including pain management,
Brazil, USA, Ukraine, Sri Lanka, Cameroon, Thailand, nutritional supplements, anti-infective, cardiac,
Argentina, Germany, Switzerland, Korea, Egypt & diabetes and hemostats, etc. The company promotes
Vietnam. It has a robust portfolio of drugs focusing on products and brands to 1,00,000+ doctors across India
women health, pain & analgesics & general medicine. and Nepal.

NEON 51 MERCURY 51
LABORATORIES LTD HEALTHCARE PVT LTD

The revenue count in FY 20-21 for Mumbai- Mumbai-based Mercury Healthcare recorded
based Neon Laboratories was Rs 19 crore in the a revenue generation of Rs 19 crore in the
biopharma space, marking a steady phase when biopharma space in FY 20-21, showing a slight
compared to the revenue generated during the previous growth when compared to the revenue generation of
year at the same figure. Since 1982, the company has Rs 18 crore during FY 19-20. The company manufactures
been constantly expanding its business by developing, stable and therapeutically effective formulations in
licensing, manufacturing and marketing new products. independent manufacturing facilities across India. The
The group presently has 3 manufacturing facilities product portfolio ranges from tablets, capsules (hard
conforming to good manufacturing practice (GMP) as and soft gelatin), syrups (liquid and dry), eye and ear
prescribed by World Health Organisation (WHO). The drops, injectables, ointments and creams, inhalers to
company offers veterinary, gynaecological, anaesthetics, veterinary tablets. The products also include surgical
and analgesic products. gloves, absorbent cotton, syringes, needles etc.

SHREYA 52 OAKNET 53
LIFE SCIENCES PVT LTD HEALTHCARE PVT LTD

Mumbai-based Shreya Life Sciences (SLS), For Bengaluru-based Oaknet Healthcare, the
the Indian arm of Shreya Group, witnessed revenue generation was Rs 15 crore during FY 20-
a revenue generation of Rs 16 crore in the 21 in the biopharma space, exhibiting a decline of
biopharma space during FY 20-21, marking a huge 12 per cent when compared to revenue generation of
dip in the business of 56 per cent in comparison to Rs 17 crore during FY 19-20. With heritage brands like
the revenue generation of Rs 36 crore in the previous Cosvate & Flucos in dermatology and Jectocos & Ferose
financial year. The company started its operations in in gynaecology, the major focus therapy areas for the
India in 2001 by acquiring the pharma division of Rallis company are cardiology, diabetology, and orthopedics.
India Ltd, a TATA Group company. SLS operates through Oaknet is an entrepreneurial venture set up in 2015 by
three strategic business units- Amadeus, AkuCare and former Lupin executive RS Raghav. The company has
BioLife. The development laboratory of the company 21 clear and forwarding (C&F) Aagents with a presence
is well equipped to carry out pre-formulation work in almost every Indian state. In addition, it has 1500
followed by optimisation to bio batch scale up. distributors and around 1.5 lakh retail chemists.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com BIOPHARMA COMPANIES RANKING 47

CORONA 53 ARISTO 53
REMEDIES PVT LTD PHARMACEUTICALS PVT LTD

The revenue count during FY 20-21 for Ahmedabad- Mumbai-based Aristo Pharmaceuticals
based Corona Remedies was Rs 15 crore in the generated revenue worth Rs 15 crore in the
biopharma space, marking a decline of 21 per cent biopharma space during FY 20-21, thereby
when compared to the revenue generated during the maintaining a steady growth in comparison to the
FY 19-20 at Rs 19 crore. For Corona, cardio metabolic and revenue generation of Rs 14 crore in the previous year.
nutraceuticals segments are the focus areas, while it has The company’s R&D centre is located in Mandideep,
a significant presence in the gynecology, infertility and Madhya Pradesh, which was established in the year
neuropathy segments. The company has a state-of-the- 2003. The centre is housed in a 12000 sq. ft. area
art manufacturing facility spread over 30,000+ sq. ft. at comprising formulation research and development,
Solan, Himachal Pradesh. The plant also has isolated and and analytical research and development section
dedicated production facilities of general, cephalosporin that is recognised by the Department of Science &
and hormonal dosage forms. Technology, Government of India.

ROCHE PRODUCTS 54 FERRING 55
INDIA PVT LTD PHARMACEUTICALS PVT LTD

For Mumbai-based Roche Products India, a revenue The Indian subsidiary of Swiss multinational
of Rs 13 crore was generated in the biopharma company Ferring Pharmaceuticals generated a
space during FY 20-21. This marks a growth of 33 revenue figure of Rs 12 crore in the biopharma
per cent for the company in comparison to the revenue space during FY 20-21, showing a huge decline
generation of Rs 9 crore in the previous fiscal. Owing to in business at 48 per cent in comparison to Rs 23
the pandemic during FY 20-21, the company observed crore generated in FY 19-20. Ferring deals with
an unprecedented demand for Tocilizumab (Actemra) reproductive medicine and women’s health with
given the significant increase in COVID-19 cases across strong presence in areas within gastroenterology
India. The company responded to this situation with and urology. FY 20-21 saw the company announce
supplies of the medicine to meet the immediate collaborations for developing live microbiome-based
emergency demand. Roche partnered with Cipla for therapeutics in reproductive medicine and maternal
the marketing and distribution of Tocilizumab. health globally.

FDC RAPTAKOS, 55
BRETT & CO. LTD
55LTD
Raptakos, Brett & Co generated revenue worth
Mumbai-based FDC generated a revenue figure Rs 12 crore during FY 20-21 in the biopharma
of Rs 12 crore in the biopharma space during FY space, exhibiting a dip of 25 per cent in the
20-21, maintaining a steady flow in the business business when compared to Rs 16 crore generated in
in comparison to the revenue generation of Rs 11 crore the previous year. The company has been serving the
in the previous year. The company had announced medical profession globally, with a wide range of high
its foray in the fight against COVID-19 by launching quality healthcare products for nearly 9 decades now.
two variants of the COVID-19 drug, Favipiravir, PiFLU Raptakos, Brett & Co. was established in 1930 by two
and Favenza, to treat mild to moderate cases of great visionaries A.Raptakos & W.H.Brett. The research
COVID-19 in India. The company has set-up globally and development laboratories have won recognition
approved, multi-location manufacturing facilities for for their work from the Department of Science and
active pharmaceutical ingredients (APIs) as well as Technology, Government of India.
finished dosage forms. These facilities are located at
Maharashtra, Goa and HP.

48 R&D NEWS BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

IIT Jodhpur IIT Kanpur transfers
unveils research
centre for Duchenne technology for bone
Muscular Dystrophy
regeneration
The Indian Institute of Technology (IIT) Jodhpur has
established a research centre for Duchenne Muscular The Indian Institute of Technology (IIT) Kanpur
Dystrophy (DMD) in collaboration with Dystrophy has transferred bone regeneration technology
Annihilation Research Trust (DART), Bengaluru and to Ortho Regenics. Titled ‘Nano-Hydroxyapatite
the All India Institute of Medical Sciences (AIIMS), based porous polymer composite scaffolds for
Jodhpur. The current therapeutic options available bioactive molecule delivery in musculoskeletal
to treat DMD are minimal and highly expensive regeneration,’ the technology has been
(over Rs 2-3 crore per child a year). Drugs are mostly developed by the Department of Biological
imported from abroad, accelerating dosing costs Sciences and Bioengineering at IIT Kanpur. It
and putting them out of reach for most families. has been licensed to overcome the problems
DMD is a rare and incurable genetic disease and related to bone and joint disorders, capable
it is the most common and fatal type of muscular of biocompatible bone regeneration. The
dystrophy, marked by gradual muscle deterioration. invention can act as a carrier for bone active
The centre at IIT Jodhpur aims to develop affordable biomolecules, delivering them directly to the
therapeutics for DMD and enhance the efficacy of implant site. The novel material is biodegradable
Antisense Oligonucleotide (AON)-based therapeutics. and has osteoinductive (bone healing process)
The AON-based therapeutics’ idea is to hide or mask and osteopromotive (material for new bone
specific exons (a segment of a DNA or RNA molecule growth) properties for bone regeneration. They
containing information coding for a protein) in a are highly biocompatible resulting in good
gene sequence. In DMD patients, one or more exons cell material interaction with osteoblast cells
can be masked with specific molecules called AON (cells responsible for mineralisation of bone
or molecular patches. Due to these challenges, DMD during bone formation and bone remodelling),
patients need personalised medicine. exhibiting high mechanical strength and
interaction between the polymer network and
the solvent. The technology provides a collagen-
nano-hydroxyapatite composite macroporous
gel, which is a potential approach for the
reconstruction of irregular bone defects and
dental applications as well.

Sudha Gopalakrishnan Brain Centre to map human brain

The Indian Institute of computing, machine learning microscopic imaging of whole
Technology, Madras (IIT-M) techniques on cutting-edge brain human brains is supported by
has launched the Sudha data. The first ongoing project of the Office of Principal Scientific
Gopalakrishnan Brain Centre to the centre titled ‘Computational Adviser to the Government of
power an ambitious global project and Experimental Platform India. Through this project, the
to map the human brain at the for High-Resolution Terapixel centre has developed a high-
cellular and connectivity levels, Imaging of ex-vivo Human throughput histology pipeline
with a focus on high-resolution Brains’ for high-throughput light that processes whole human
brain imaging. This state-of- brains into high-resolution digital
the-art centre aims to become a images. Using this technology
world-renowned research centre, platform, the centre is imaging
generating unprecedented human post-mortem human brains of
brain data, scientific output and different types and ages. The
technology tools. IIT-M plans to centre has already acquired whole
train hundreds of undergraduate brain serial-section cell-resolution
and postgraduate students at volumes of three developing
this centre in neuroscience and brains to date.

BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com SUPPLIERS NEWS 49

Waters brings new tandem Promega introduces
quadrupole mass spectrometer
Xevo TQ Absolute new Lumit

Waters Corporation has introduced the new Xevo TQ Immunoassays for
Absolute system, the most sensitive and compact benchtop
tandem mass spec in its class. Waters’ newest high- ELISA users
performance mass spectrometer is up to 15X more sensitive
for quantifying negatively ionizing compounds than its Researchers studying immunity and
predecessor and is 45 per cent smaller and uses up to 50 inflammation now have a faster, easier
per cent less electricity and gas supply than other high- alternative to traditional enzyme-linked
performance tandem quadrupole mass spectrometers immunosorbent assays (ELISAs) with new
available on the market. The Xevo TQ Absolute is designed to Promega bioluminescent assays launched.
help pharmaceutical, food and beverage, and environmental The Lumit Cytokine Immunoassays can
analytical laboratories meet regulations requiring trace-level quantitatively detect
quantitative mass spectrometry analyses for a broad set of released cytokines from
applications. For optimal performance, Waters pairs the cell culture samples
Xevo TQ Absolute mass spectrometer with Waters’ ACQUITY in 70 minutes. These
Premier UPLC System with MaxPeak HPS technology luminescent assays
which eliminates non-specific adsorption of compounds are scalable for use in
containing phosphate basic research or high-
and/or carboxylate throughput screening
groups and improves for drug discovery and
their recovery. development. Cytokines
It incorporates are signalling molecules
thoughtful design critical for regulating
features that inflammation and immune responses.
enable consistent While traditional ELISA-based cytokine
and reproducible detection methods can require hours of
analyses, allowing hands-on time to produce results, Lumit
labs to maintain Cytokine Immunoassays offer a simpler,
performance and faster protocol. Features of these kits
uptime for longer include- No-wash protocol; Add-and-read
periods in between assay format; and Broad linear range
routine cleaning and with no dilution steps required. Ready-to-
service intervals. use assays are available for six common
targets: IL-1β IL-2, IL-4, IL-6, IL-10,
IFN-γ and TNF-α.

Agilent Technologies opens Centre for
Excellence at Gujarat Technological University

Agilent Technologies Inc. science research. This new CoE of its new office in the city of
has announced a Centre for instrumentation laboratory is Ahmedabad. This new workspace
Excellence (CoE) lab facility intended as a shared educational encourages design thinking
in Gujarat Technological and research space that will offer elements, brings vibrancy, and
University’s (GTU) premises. tremendous opportunities to has an efficient layout to serve
The facility will be available for advance scientific discovery and their customers even better. Due
faculty members of GTU, their validation, while also serving as to the rapid speed of technological
students, and Agilent team a valuable technology resource innovation, universities and
to study and develop novel to academia. Agilent India also other educational and research
application workflows in the achieved a significant milestone institutions may find it difficult to
areas of analytical chemistry, in strengthening its footprints keep up with the latest technology
biopharmaceuticals, and life in India with the inauguration and training requirements.

50 LET’S TALK HEALTH BIOSPECTRUM | MAY 2022 | www.biospectrumindia.com

Why Asthma Continues to Assail

The burden of asthma and allergic rhinitis has diagnosis of asthma.
gradually risen during the last two decades. The most significant direct harm from over-
There are an estimated 38 million people with
asthma in India, with overall prevalence of asthma diagnosis is likely to be in patients whose symptoms
in children being 6– 8 per cent. Nearly 60–70 per have led to them being inappropriately commenced
cent of patients have co-existing allergic rhinitis and on oral corticosteroids (OCS). Although extremely
asthma, and it remains unclear at present how well useful in the short-term management of significant
the allergic rhinitis is controlled amongst asthmatics. asthma exacerbations, medium- to long-term OCS
use is associated with significant treatment-related
In many cases, asthma is a lifelong condition morbidity.
that a person can control using medication and
by avoiding triggers that cause asthma attacks. To Besides over-diagnosis, under-diagnosis of
add to it, the asthmatic condition could either be asthma is another common problem occurring
allergic, non-allergic, seasonal, occupational, exercise due to medical professionals failing to recognise
induced, or severe in nature. Out of these, allergic the disease, and perhaps attributing symptoms to
asthma is the most common one. And one of the obesity, deconditioning, cardiac disease or other
major factors contributing to this is the growing air causes. Studies have shown that many patients died
pollution in the country. of asthma while being managed as mild or moderate
asthma. While this does not directly deal with under-
Children are one of the most vulnerable diagnosis, it is an important reminder that the under-
populations to the harmful effects of air pollution treatment of asthma remains a problem.
and serious concerns have been raised about the lung
health of over 6 million children living in Delhi alone. If this was not enough, a recent study has revealed
Children breathe greater volumes of air than adults that higher exposure to Bisphenol A, a chemical used
and many of the pollutants in the inhaled air interfere in the manufacturing of plastics and resins found in
with the proper growth and development of the lungs. many consumer products such as food cans, reusable
bottles and toys, in the womb is associated with
Chronic exposure to high levels of air pollution increased risk for asthma and wheezing in childhood.
has been shown to be associated with a greater risk Another recent study has suggested that a significant
of developing respiratory tract infections, asthma, amount of genetic risk for asthma is likely mediated
and stunted lung growth. According to a paper through altered gene expression within the airway
published in a journal called Children in April 2021, epithelium. On the other hand, immunologists
air pollution has been shown to be associated with from the US have stated that people with allergic
the development of obesity, which further contributes asthma might actually be less susceptible to severe
to the development of asthma in children. COVID-19.

Moreover, there is no single gold standard test to These observations clearly indicate that there is
diagnose asthma, and there are significant differences an urgent need to strategise and prioritise asthma
between the suggested algorithms in commonly used research in India. The government and industry
guidelines. For instance, obese patients are known to should take into account current barriers to the
have more respiratory symptoms than the non-obese, provision of basic asthma and allergy care. Further,
and so one might expect them to have an even greater funds for research are limited since infectious
rate of over-diagnosis of asthma. diseases, respiratory diseases, oncology and
cardiovascular conditions take precedence over
Patients are, thereafter, often on long-term asthma and allergy.
inhaled therapy unnecessarily, leading both to
potential side-effects and significant ongoing Dr Manbeena Chawla
healthcare costs, as these drugs are likely Executive Editor
recommended to be used for many years after a
[email protected]